

NHS South Yorkshire Integrated Medicines Optimisation Committee (IMOC)

Traffic Light Drug List

Jul-26

*****This list is in development and is being led by the SY IMOC, currently it does not include medicines where the 4 places (Barnsley, Doncaster and Bassetlaw, Rotherham and Sheffield) have previously agreed at place based TL status. Harmonisation of placed based TLDL is underway with the long-term vision to have one TLDL for South Yorkshire.**

Due to the extensive number of green drugs, currently not all will be listed within the SY TLDL. During the process of merging the 4 place TLDLs across South Yorkshire, green drugs will be added to the IMOC TLDL as

*****Formulary status of these drugs will be decided by each Place*****

	Grey Traffic light Status		Red traffic Light Status		Green Traffic Light Status
	Amber Traffic Light Status		Amber G Traffic Light Status		

[fer to the user guide for classification rationa Click here](#)

Remember : Control + F to search this list

SY Place based Formularies :	
Barnsley Place Formulary	Rotherham Place Formulary
Doncaster Place Formulary	Sheffield Place Traffic Light Drug List

Traffic Light Status	Drug/Product	Brand name	Rationale / criteria	Notes	Date Considered	Review date	Relevant Links
Grey	Aceclofenac		3	Non-steroidal anti-inflammatory	Jun-23		
Grey	Adagrasib		6	Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)	Aug-25		NICE TA1076
Grey	Adrenaline (nasal spray formulation) (Dual Traffic Light status)	EURneffy®	7	Emergency treatment of severe allergic reactions (anaphylaxis)	Dec-25		
Grey	Afamelanotide		1	Erythropoietic protoporphyria	Sep-23		
Grey	Agomelatine		3	Major Depression	Jun-23		NICE TA821
Grey	Alimemazine (dual traffic light classification)		4	All licensed indications- urticaria and pruritus(already traffic lighted Amber if initiated for sleep disorders in children by tertiary sleep service in SCH (unlicensed indication)	Feb-25		
Grey	Aliskiren		1	Hypertension	Jun-23		Link to NHSE LLP1
Grey	Almotriptan		4	Refer to Place based formularies / guidelines for alternative listing	Jun-24	Jun-25	Link to NHSE LLP1
Grey	Amantadine (Multiple traffic light classification)		2	Influenza	Jun-23		
Grey	Amifampridine (3,4 diaminopyridine phosphate)		1	Lambert-Eaton Myasthenic Syndrome (LEMS) in adults	Jun-23		
Grey	Anakinra (dual traffic light classification)		2	Rheumatoid arthritis in adults	Jun-23		NICE NG100 Also see reference to Red traffic light status
Grey	Angiotensin II		2	Treatment of refractory hypotension in adults with septic or other distributive shock	Apr-24		

Grey	Antimalarials (dual traffic light combination)		2	Prophylaxis treatment of malaria	Apr-24		Drugs for malaria prophylaxis are not prescribable on the NHS. Chloroquine & atovaquone 250 mg / proguanil 100mg is available to buy over-the-counter. Mefloquine and doxycycline are only available on private prescription.
Grey	Aprocitentan		6	Resistant hypertension	Apr-25		
Grey	Armour thyroid (desiccated thyroid extract)		1	Hypothyroidism	Jun-23		Link to SPS advice
Grey	Atorvastatin 30mg and 60mg tablets		4	For cost-effective prescribing it is recommended that for patients requiring a 30mg or 60mg dose to use 10mg or 20mg tablets	Jun-24	Jun-25	
Grey	Avanafil		4	Erectile dysfunction	Feb-24		
Grey	Axicabtagene ciloleucel (dual Traffic light status)		2	Refractory follicular lymphoma	Jul-23		NICE TA894
Grey	Azathioprine 75mg & 100mg strengths (dual Traffic Light Status)		3		Apr-24		
Grey	Azilsartan		4	Hypertension	Feb-24		
Grey	Baloxavir marboxil		2	Uncomplicated influenza and post exposure prophylaxis of influenza in patients aged 12 years and above	Jun-23		
Grey	Baloxavir marboxil		7	Treating and preventing influenza in children 1 to 11 years (terminated appraisal)	Mar-26		NICE TA1135
Grey	Bemiparin		6	All licensed indications	Jun-23		

Grey	Calcifediol	Domnisol®	7	Treatment of vitamin D deficiency in adults, prevention of vitamin D deficiency in adults with identified risks, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency	Dec-23		
Grey	Cangrelor tetrasodium		7	Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy	Jan-26		NICE TA1102
Grey	Casirivimab plus imdevimab		1	Covid-19 Treatment	Jun-23		NICE TA878
Grey	Cedazuridine + decitabine		2	Acute myeloid leukaemia	Mar-24		
Grey	Cemiplimab		2	with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer	Dec-25		NICE TA1108
Grey	Cerliponase alfa		7	Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2	Mar-26		HST34
Grey	Chikungunya vaccine		6	Active immunisation for the prevention of disease caused by chikungunya virus	Aug-25		
Grey	Chondroitin (all salts, all strengths)		1,2	All Indications	Jul-23		In NHSE guidance
Grey	Ciclesonide	Alvesco®	4	Refer to Place based formularies / guidelines for alternative listing	Sep-23		
Grey	Cilostazol		2	Intermittent claudication in patients without rest pain and no peripheral tissue necrosis	Jul-23		NICE TA223

Grey	Ciltacabtagene autoleucel		6	Treatment of adults with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide	Mar-25		
Grey	Ciprofibrate		4	Refer to Place based formularies / guidelines for alternative listing	Jul-24		
Grey	Clascoterone		6	Topical treatment of acne vulgaris in patients aged ≥12 years	May-25		
Grey	Clascoterone		6	For treating acne vulgaris in people 12 years and over (terminated appraisal)	Nov-25		NICE TA1105
Grey	Clobetasol propionate/neomycin sulphate/nystatin 0.5mg/5mg/100,000 IU/g Cream/ointment		4	Refer to Place based formularies / guidelines for alternative listing	Jul-23		
Grey	Cobimetinib		2	Unresectable or metastatic melanoma in adults	Jul-23		NICE TA414
Grey	Co-diovan		4	Hypertension	Sep-23		For cost-effective prescribing it is recommended that valsartan plus bendroflumethiazide should be prescribed separately
Grey	Concizumab		6	Treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)	May-26		NICE TA1124
Grey	Co-Proxamol		1	All licensed indications	Jun-23		NHSE Guidance
Grey	Cyanocobalamin 50 microgram tablets (dual traffic light combination)		1	Dietary Supplement	May-23		NHSE items that should not routinely prescribed Also see reference to Green traffic light status
Grey	Darifenacin		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		

Grey	Darvadstrocel		2	Fistulas (perianal) in adult patients with non-active/mildly active luminal Crohn's disease.	Sep-23		
Grey	Decitabine (Including combinations)		7	Myeloid Leukaemia	Nov-24		Decitabine NICE Information
Grey	Deflazacort		4	Steroid	Feb-24	Feb-25	
Grey	Dekas plus liquid (dual traffic light classification)			Non- Cystic fibrosis patients Also see Green for children under 3 with cystic fibrosis	Oct-23		
Grey	Dengue vaccine	Qdenga®	1	Prevention of dengue disease in individuals aged ≥4 years	Oct-23		
Grey	Depemokimab		7	Treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)	Feb-26		NICE TA1123
Grey	Dexketoprofen		5	Nonsteroidal anti- inflammatory drug (NSAID)	Feb-24		
Grey	Dicycloverine Hydrochloride tablets		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		Medicines Optimisation Information
Grey	Diphtheria + tetanus + pertussis vaccine		6	Active immunisation against tetanus, diphtheria and pertussis in persons aged ≥4 years as a booster following primary immunisation. Also for passive protection against pertussis in early infancy following maternal immunisation during pregnancy	May-24		
Grey	Donanemab		6	Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adults that are apolipoprotein E ε4 heterozygotes or non-carriers	Jan-25		
Grey	Dosulepin		1	Depressive illness, particularly where sedation is required	Jun-23		Link to NHSE LLP1
Grey	Doxazosin MR preparations		1	Hypertension	Jun-23		Link to NHSE LLP1

Grey	Doxepin		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		
Grey	Doxepin cream		3	Pruritus in eczema	Jul-23		
Grey	Dutasteride 500mcg plus tamsulosin 400microgram		4	For cost-effective prescribing it is recommended that Dutasteride and Tamsulosin are prescribed separately	Sep-23		
Grey	Efgartigimod for treating antibody-positive generalised myasthenia gravis		2	Efgartigimod for treating antibody-positive generalised myasthenia gravis	Jul-25		NICE TA 1069
Grey	Elacestrant		6	Use as monotherapy for the treatment of postmenopausal women and men with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor	Nov-24		
Grey	Elinzanetant	Lynkuet®	6	Indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause	Jul-26		NICE TAs in development
Grey	Elotuzumab		7	For previously treated multiple myeloma	May-25		Elotuzumab NICE information
Grey	Entrectinib		7	for treating NTRK fusion-positive solid tumours in people 12 years and over.	Feb-26		NICE TA1118
Grey	Epcoritamab		5	Monotherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy	Feb-24		
Grey	Erdosteine		3	Symptomatic treatment of acute exacerbations of chronic bronchitis	Jul-25		

Grey	Eroxon Stimgel		7	Treatment of erectile dysfunction in adult men [medical device – gel formulation of volatile solvent components]	Jun-23		
Grey	Esketamine		2	Major depressive disorder in adults at imminent risk of suicide	Jul-23		NICE TA899
Grey	Esketamine Nasal spray		2	Depression	Sep-23		
Grey	Eszopiclone		7	Insomnia	Apr-25		
Grey	Eyelid hygiene preparations		3	Examples : wipes,lotions	Sep-23		
Grey	Fampridine		2	Multiple sclerosis	Sep-23		NICE NG220
Grey	Fentanyl (Immediate release)		1	For patients not undergoing palliative care treatment as per NHSE guidelines	Dec-23		NHS E Guideline
Grey	Fluoxetine 10mg tablets (refer to the green entry for other strengths/formulations)		4	Cross reference to green traffic light entry for other strengths/formulations	Mar-26		The capsule formulation has a significantly lower acquisition cost
Grey	Flurbiprofen tablets		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		
Grey	Fluvastatin 80mg		4	Refer to Place based formularies/guidelines for alternative listing	Sep-23		
Grey	Fosdenopterin		7	Treating molybdenum cofactor deficiency type A (terminated appraisal)	Aug-25		NICE TA1078
Grey	Gamolenic acid (Evening Primrose Oil)		3		Sep-23		
Grey	Ganaxolone		2	Treating seizures caused by CDKL5 deficiency disorder in people 2 years and over	Mar-25		
Grey	Gefapixant		7	Refractory or unexplained chronic cough	Jun-24		

Grey	Givinostat		6	Treatment of Duchenne muscular dystrophy in patients aged 6 years and older	Apr-26		NICE TA in development
Grey	Glasdegib		1	Terminated NICE TA	Sep-23		NICE TA646
Grey	Glucosamine and chondroitin		1		Sep-23		NHSE guidance
Grey	Gluten Free products			Coeliac Disease, gluten sensitive enteropathies, dermatitis herpetiformis or other gluten intolerances in line with SYICB position statement	Jan-26		SY Gluten Free information
Grey	Gonadotrophin releasing hormone (GnRH) analogues drugs- medicines that consist of, or contain, buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin.		2	Used to suppress puberty as part of treating gender incongruence or gender dysphoria in children and young people who are under 18 years of age	Jun-24		NHSE Information
Grey	Herbal treatments		1	Not Recommended	Oct-23		NHSE document
Grey	Homeopathic treatments		1	Not Recommended	Oct-23		NHSE document
Grey	Human alpha1-proteinase inhibitor		7	Treating emphysema	May-24		
Grey	Hyaluronic acid Intra-articular injections		2	Do not offer intra-articular hyaluronan injections to manage osteoarthritis	Oct-23		NICE NG226
Grey	Idecabtagene vicleucel		6	Treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)	Aug-25		NICE TA 1084
Grey	Immunestrant		7	Immunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)	Jul-26		NICE TA 1168

Grey	Imlunestrant	Inluriyo®	6	Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen (for biomarker-based patient selection, see section 4.2). In pre- or perimenopausal women, or men, Inluriyo should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.	Jul-26	NICE TA in development
Grey	Inavolisib		6	Use in combination with palbociclib and fulvestrant for the treatment of adults with PIK3CA-mutated, oestrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.	Apr-26	NICE TA in development
Grey	Inebilizumab		7	Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)	Jun-26	NICE TA 1151
Grey	Inositol nicotinate		2	Intermittent claudication in people with peripheral arterial disease	Oct-23	
Grey	Insulin needles >£5 per 100 needles		4		Sep-23	Refer to Place based formularies/ guidelines supported by NHSE document
Grey	Iptacopan		1,6	Treating complement 3 glomerulopathy	Dec-25	NICE TA1107
Grey	IQoro		3	Neuromuscular training device	Feb-23	

Grey	Ketoprofen (topical)		3	Areas of skin treated with Ketoprofen 2.5 % Gel should not be exposed to direct sunlight, or solarium ultraviolet light, either during treatment or for two weeks following treatment discontinuation, in order to avoid phototoxicity reactions and photoallergy	Oct-23		
Grey	Lazertinib		6	Advanced non-small cell lung cancer	Jun-25		On publication of NICE TA
Grey	Lecanemab		6	Alzheimer's disease	Feb-25		
Grey	Leniolisib phosphate		6	Indicated for the treatment of activated phosphoinositide 3- kinase delta (P13Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older.	Mar-25		
Grey	Levodopa inhalation powder	Inbrija®	7	Intermittent treatment of episodic motor fluctuations (OFF episodes) in adults with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor	Nov-25		
Grey	Loxapine		2	Mild-to-moderate agitation in patients with schizophrenia or bipolar disorder	Oct-23		
Grey	Lutein and antioxidants (All dietary antioxidants and supplements to prevent AMD)		1	Age related macular degeneration (AMD)	Oct-23		NHSE document
Grey	Melphalan flufenamide		7	Relapsed or refractory multiple myeloma	Jun-24		
Grey	Memantine orodispersible tablets (see amber G entry for other formulations of memantine)		4	Memantine tablets are 1st line. If oral solution is required for cost-effective prescribing it is recommended that oral solution is prescribed where clinically appropriate. See Place guidance for further prescribing information.	Nov-23	Nov-24	

Grey	Mepolizumab		8	maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils Grey classification will be reviewed when a plan to support implementation has been agreed.	Jul-26		NICE TA 1166
Grey	Methocarbamol		1	Short-term symptomatic relief of muscle spasm	Nov-23		
Grey	Methylnaltrexone bromide injection		2	Exception prescribe on advice of the specialist Palliative Care team	Nov-23		
Grey	Minocycline		1	Acne Vulgaris and Acne Rosacea	Nov-23		NHSE guidelines
Grey	Mosunetuzumab		2	Follicular lymphoma	Nov-23		NICE Information
Grey	Naltrexone/bupropion prolonged-release tablets		2	Weight Management	Jul-23		NICE TA494
Grey	Necitumumab		2	Lung cancer	Nov-23		Necitumumab NICE information
Grey	Netarsudil + latanoprost 50micrograms/200 micrograms in 1mL eye drops		6	Primary open-angle glaucoma or ocular hypertension	Sep-23		
Grey	Nintedanib		6	Treating fibrosing interstitial lung disease in people 6 to 17 years	Dec-25		Nintedanib NICE Informormation
Grey	Niraparib + abiraterone		6	Use with prednisone or prednisolone for the treatment of adults with metastatic castration-resistant prostate cancer and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated	Apr-26		NICE TA in development
Grey	Nogapendekin alfa inbakicept		7	Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)	Jul-26		NICE TA 1163

Grey	Olipudase alfa		7	Treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B	May-25		NICE hst32
Grey	Olmesartan and amlodipine		4	For cost-effective prescribing it is recommended that olmesartan and amlodipine prescribed separately	Nov-23		
Grey	Omaveloxolone		7	Treating Friedreich's ataxia in people 16 years and over	Dec-25		NICE TA1061
Grey	Omega-3 fatty acids (Eicosapentaenoic acid /Docosahexaenoic acid)		1	For the primary and secondary prevention of cardiovascular events	Sep-23		NHSE guidance
Grey	Osilodrostat		1,7	Endogenous Cushing's syndrome	Nov-23		
Grey	Oxerutins		3	Oedema associated with chronic venous insufficiency	Nov-23		
Grey	Oxybutynin hydrochloride	Vesxxx	7	Managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)	Jun-26		NICE TA 1154
Grey	Padeliporfin		2	For untreated, unilateral, low-risk prostate cancer in adults	Dec-23		
Grey	Palopegteriparatide		6	Indicated for the treatment of adults with chronic hypoparathyroidism-	Oct-24		NICE TA in development
Grey	Paracetamol and tramadol combination		1	Analgesic	Dec-23		NHS E Guideline
Grey	Pegaptanib		2	Neovascular age related macular degeneration	Dec-23		
Grey	Pegylated liposomal irinotecan		7	Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer	May-25		NICE TA1052
Grey	Pentoxifylline		2	Intermittent claudication in people with peripheral arterial disease	Jul-23		NICE TA223
Grey	Perindopril arginine		1	Angiotensin converting enzyme (ACE) inhibitors	Dec-23		NHS E Guideline

Grey	Phenylephrine OTC preparations (oral/nasal) (dual classification)		1	For OTC preparations. See also see red list	Oct-25		
Grey	Pioglitazone and Metformin combination tablets		4	For cost-effective prescribing it is recommended that Pioglitazone and Metformin are prescribed separately	Dec-23	Dec-24	
Grey	Piroxicam (oral)		3	Nonsteroidal anti-inflammatory drug (NSAID)	Dec-23		
Grey	Pirtobrutinib	Jaypirca®	6	Use as monotherapy for the treatment of adults with relapsed or refractory mantle cell lymphoma who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor, and use as monotherapy for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia who have been previously treated with a BTK inhibitor	Dec-25		
Grey	Pitolisant (dual classification)		2	Excessive daytime sleepiness caused by obstructive sleep apnea. See also Red for other indications	Dec-25		
Grey	Ranitidine		3	H2-receptor antagonists	Dec-23	Dec-24	
Grey	Recombinant Parathyroid hormone		1,6	All licensed indications	Oct-25		Parathyroid hormone NICE information
Grey	Rehydration solutions/sachets (dual traffic light status)		1	Self care-acute Diarrhoea (adults)	Feb-24		SY Selfcare Guide
Grey	Resperate® Device		1		Dec-23		
Grey	Riboflavin		2,3	Migraine	Feb-24		NICE CG150 – can be purchased OTC
Grey	Rizatriptan lyophilisate	Maxalt®	4	Migraine	Feb-24	Feb-25	

Grey	Rosuvastatin Capsules		4	For cost effective option prescribe tablets, exception being opening capsules for swallowing difficulties & mixed with soft food for oral administration or administered via nasogastric tube.	Jul-24	Jul-25	
Grey	Rubefaciants		1	Self- care - as per NHSE Guidelines	Dec-23		NHS E Guideline
Grey	Rupatadine		4	Refer to Place based formularies / guidelines for alternative	Dec-23	Dec-24	
Grey	Satralizumab		7	Preventing relapses in neuromyelitis optica spectrum disorders	May-24		Sarilumab NICE Information
Grey	Satralizumab		2	Use as a monotherapy or in combination with immunosuppressive therapy for the treatment of neuromyelitis optica spectrum disorders in adults and adolescents aged ≥12 years who are anti-aquaporin-4 IgG seropositive	Apr-24		
Grey	Sebelipase alfa (dual traffic light combination)		7	Lysosomal acid lipase (LAL) deficiency - long term enzyme replacement therapy (ERT) cross reference to Red TLS	Feb-24		
Grey	Seladelpar	Livdelzi®	6	Treatment of primary biliary cholangitis, including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA	Dec-25		
Grey	Self-care medicines - All Conditions for which over the counter items should not routinely be prescribed in primary care		5	Various Over the Counter medicines That are considered to be self-limiting i.e short term symptoms	Jun-23		
Grey	Selinexor		6	Multiple myeloma	Mar-24		

Grey	Sildenafil brand: Viagra® (For Erectile Dysfunction) (multiple traffic light classifications)	Viagra®	4	Erectile Dysfunction. See also sildenafil entry in green and red sections. Follow Place formularies / guidelines for further information	Apr-25		
Grey	Silk Garments		1	In line with NHSE guidance Items not to be routinely prescribed in primary care	Dec-23		NHS E Guideline
Grey	Simple eye ointment		4	Refer to Place based formularies / guidelines for alternative	Dec-23		
Grey	Sirolimus		6	for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over	Jun-24		
Grey	Sirolimus gel		6	Treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged ≥6 years	Dec-23		
Grey	Sodium Phenylbutyrate (Dual Classification)		6	For treating amyotrophic lateral sclerosis, see red traffic light list for other indications	Nov-25		Sodium Phenylbutyrate NICE information
Grey	Sulindac		3,4	Gout	Dec-23	Dec-24	
Grey	Sulthiame		6	Rolandic epilepsy	Apr-25		
Grey	Sumatriptan + naproxen sodium combination		4,7	Acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient	Jul-25		
Grey	Sumatriptan dispersible tablets	Imigran® Radis	4	Migraine	Feb-24	Feb-25	
Grey	Sun protection		Self care -1	Self care - Exception as per Advisory Committee on Borderline Substances (ACBS) approved indications.	Dec-23		
Grey	Tabelecleucel		2	Treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus	Nov-23		NICE TA923
Grey	Tadalafil 2.5mg only		4		Jul-24		

Grey	Tadalafil brand: Cialis® (For Erectile Dysfunction) (multiple traffic light classifications)	Cialis®	4	Erectile Dysfunction . See also tadalafil entries in green section and red sections. Follow Place formularies / guidelines for further information	Apr-25		
Grey	Tafamidis (dual traffic light combination)		2	Wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults Also see reference to Red traffic light status	Dec-23		
Grey	Tamsulosin plus solifenacin combination tablets		4	For cost-effective prescribing it is recommended that Tamsulosin and Solifenacin are prescribed separately	Dec-23	Dec-24	
Grey	Tamsulosin MR tablets		4	For cost-effective prescribing it is recommended that Tamsulosin MR capsules are prescribed	Dec-23	Dec-24	
Grey	Tarlatamab		6	Small cell lung cancer	Apr-25		
Grey	Telmisartan & Hydrochlorothiazide	Micardis Plus®	4	Refer to Place based formularies / guidelines for alternative listing	Nov-23		
Grey	Temsirolimus		2	All licensed indications	Feb-24		Temsirolimus NICE Information
Grey	Teplizumab		6	To delay the onset of Stage 3 type 1 diabetes in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes	Feb-26		TA expected April 2026
Grey	Teprotumumab	Tepezza®	6	Use in adults for the treatment of moderate to severe thyroid eye disease	Dec-25		
Grey	Tiaprofenic acid		3	Pain and inflammation in rheumatic disease and other musculoskeletal disorders	Feb-24		Important safety information For tiaprofenic acid CSM advice
Grey	Tirzepatide weight management - any use outside of NICE TA1026 criteria [Multiple traffic light classifications]			Any patients that fall outside of NICE TA1026 criteria.	Nov-25		NICE TA1026
Grey	Tislelizumab		7	Terminated appraisals	Jul-25		NICE TA 1068 & TA 1072- terminated appraisals

Grey	Tixagevimab plus cilgavimab		2	Preventing COVID-19	Jul-23		NICE TA900
Grey	Tofersen	Qalsody®	6	Treatment of adults with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene	Dec-25		
Grey	Toripalimab	Loqtorzi®	6	In combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. In combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.	Jul-26		NICE TA in development
Grey	Trastuzumab deruxtecan		6	Treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments	Dec-25		
Grey	Travel Vaccines		1	Except for: cholera, diphtheria/tetanus/polio, hepatitis A, typhoid	Oct-23		NHSE Guidance
Grey	Trimipramine		1	Antidepressant	Jul-23		NHS E Guidance
Grey	Vinflunine		2	Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract	Feb-24		
Grey	Vitamin supplements and tonics		1	In line with SY Selfcare Guide	Feb-24		SY Selfcare Guide
Grey	Zilucoplan		6	Use as an add-on to standard therapy for the treatment of generalised myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive	May-24		

Grey	Zuranolone	Zurzuvae®	6	Treatment of moderate or severe postnatal depression in adults following childbirth	Dec-25		
Red	Rezafungin		1,6	Treatment of adults with invasive candidiasis	May-24		
Red	Abacavir(including combinations)		1,6	HIV infection	Feb-24		
Red	Abaloparatide		1,6	Treating osteoporosis after menopause	Oct-24		
Red	Abatacept		1,6	In line with positive NICE TA recommendations	Feb-24		Abatacept NICE information
Red	Abciximab		1,6	Monoclonal antibody	Feb-24		
Red	Abemaciclib		1,6	In line with positive NICE TA recommendations	Feb-24		Abemaciclib NICE Information
Red	Abiraterone		1,6	In line with positive NICE TA recommendations	Feb-24		Abiraterone NICE Information
Red	Abrocitinib		1,6	Atopic dermatitis	Feb-24		
Red	Acalabrutinib		1,6	Chronic lymphocytic leukaemia	Feb-24		
Red	Acetylcysteine ampoules		1	Emergency Treatment of Poisoning (paracetamol)	Feb-24		
Red	Aciclovir IV		1,6		Apr-24		
Red	Acitretin		1	Psoriasis	Feb-24		
Red	Acoramidis		1,6	Treating transthyretin amyloidosis with cardiomyopathy	Feb-26		NICE TA 1121
Red	Activated Charcoal		1,6	Emergency Treatment of Poisoning ('many oral poisons')	Apr-24		
Red	Activated Protein C	Ceprotrin®	1,6	Congenital protein C deficiency	Apr-24		
Red	Adalimumab		1,2,6	In line with positive NICE TA recommendations	Jun-23		Adalimumab NICE information
Red	Adefovir		1	Chronic hepatitis B	Feb-24		
Red	Adenosine	Adenocor®	1,6	Supraventricular arrhythmias	Apr-24		
Red	Afatinib		1,6	Non-small cell lung cancer	Feb-24		
Red	Aflibercept		1,2	In line with positive NICE TA recommendations	Jun-23		Aflibercept NICE information
Red	Agalsidase alfa & beta		1,6	Fabry's disease	Apr-24		
Red	Albendazole		1,6		Apr-24		

Red	Albutrepenonacog alfa		1	Treatment and prophylaxis of bleeding in patients with haemophilia	Feb-24		
Red	Aldesleukin		1,6	In line with positive NICE TA recommendations	Apr-24		
Red	Alectinib		1,6	for adjuvant treatment of ALK-positive non-small-cell lung cancer	Dec-24		Alectinib NICE Information
Red	Alemtuzumab		1,6	In line with positive NICE TA recommendations	Jul-24		Alemtuzumab NICE information
Red	Alirocumab		1,6	Primary hypercholesterolaemia	Feb-24		
Red	Alitretinoin		1	Eczema - refractory chronic hand (severe)	Feb-24		
Red	All human coagulation factor IX		1	All licensed indications	Oct-25		
Red	All Intravenous nutrition		1,6		Apr-24		
Red	Alpelisib	Piqray®	1,6	Indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy	Apr-24		
Red	Alteplase		1,6		Apr-24		
Red	Ambrisentan		1	Pulmonary arterial hypertension	Feb-24		
Red	Amikacin		1,6	In line with positive NICE TA recommendations	Apr-24		
Red	Aminolevulinic acid products		1,5	Actinic keratosis on face, scalp (mild to moderate) and other body regions Field cancerisation. Basal cell carcinoma (superficial and/or nodular)	Feb-24		
Red	Aminophylline IV		1,6		Apr-24		

Red	Amivantamab (including in combination)		1,6	In line with positive NICE TA recommendations	Apr-24		Amivantamab NICE Information
Red	Amphotericin		1,6	Antifungal	Apr-24		
Red	Anagrelide		1,6	Polycythaemia vera, Thrombocytosis,	Apr-24		
Red	Anakinra (dual traffic light classification)		1,6	Still's disease & Gout Also see reference to Grey traffic light status	Feb-24		
Red	Andexanet alpha		1,6	In line with positive NICE TA recommendations	Feb-25		Andexanet+alfa NICE Information
Red	Anhydrous sodium thiosulfate		1,6	In line with positive NICE TA recommendations	Feb-25		Anhydrous+sodium+thiosulfate NICE Information
Red	Anidulafungin		1,6	Invasive candidiasis	Apr-24		
Red	Anti-D (Rh0) Immunoglobulin		1,6		Apr-24		
Red	Antihemophilic factor/Von Willebrand factor complex		1,6	Congenital Von Willebrand Disease	Apr-24		
Red	Anti-lymphocyte immunoglobulin (horse) (Atgam®)		1,6	Treatment of acquired moderate to severe aplastic anaemia	Apr-24		
Red	Antimalarials (dual traffic light classification)		1,6	For treatment of malaria	Apr-24		
Red	Antithrombin		1,6	VTE - Prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency	May-24		
Red	Anti-thymocyte immunoglobulin (Rabbit)		1,6	Immunosuppression in solid organ transplantation	Oct-25		
Red	Apalutamide		1,6	Prostate Cancer (non-metastatic castration-resistant)Metastatic Hormone Sensitive Prostate Cancer	May-24		
Red	Apraclonidine		1,6	Glaucoma (short-term adjunctive therapy of chronic glaucoma)	May-24		

Red	Apremilast		1,6	In line with positive NICE TA recommendations	Feb-24		Apremilast NICE information
Red	Aprepitant		1,6	Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12.	May-24		
Red	Arachis hypogaea		1,6	Peanut Allergy	May-24		
Red	Argatroban		1,6	Anticoagulation of patients with heparin-induced thrombocytopenia type II requiring parenteral antithrombotic therapy	May-24		
Red	Argipressin		1,6	Indicated in adults for the treatment of diabetes insipidus, when this is not of nephrogenic origin, and for control of bleeding from oesophageal varices.	May-24		
Red	Arsenic trioxide		1,6	Acute promyelocytic leukaemia (relapsed/refractory)	May-24		
Red	Artesunate		1	Initial treatment of severe malaria in adults and children	Dec-24		
Red	Asciminib		1,6	Chronic myeloid leukaemia	May-24		
Red	Ascorbic Acid Injection/Infusion		1,6	Treatment of clinical vitamin C deficiency not amenable to dietary supply or oral replacement therapy in adults	May-24		
Red	Asenapine		1,6	Manic episodes (moderate to severe) associated with bipolar I disorder	May-24		
Red	Asfotase alfa		1,6	Hypophosphatasia - long term enzyme replacement therapy (ERT)	May-24		
Red	Asparaginase		1,6	Acute lymphoblastic leukaemia	May-24		
Red	Ataluren		1,6	Duchenne muscular dystrophy	May-24		
Red	Atazanavir (including combinations)		1,6	HIV Infection in combination with other antiretroviral drugs	May-24		
Red	Atezolizumab		6	In line with positive NICE TA recommendations	Apr-25		Atezolizumab NICE Information

Red	Atidarsagene autotemcel		1,6	Metachromatic leukodystrophy	May-24		
Red	Atovaquone		1,6		May-24		
Red	Autologous cell/blood related		1,6	In line with positive NICE TAs	Oct-24		Autologous NICE information
Red	Avacopan		1,6	NHSE commissioned.	May-24		
Red	Avalglucosidase alfa		1,6	Pompe disease	Apr-23	Apr-27	NICE TA821
Red	Avapritinib		1,6	Treating advanced systemic mastocytosis	Dec-24		Avapritinib NICE Information
Red	Avatrombopag		1,6	In line with positive NICE TA recommendations	May-24		Avatrombopag NICE Information
Red	Avelumab (including in combination)		1,6	As per licenced appropriate NICE TA	Jun-23		Avelumab NICE information
Red	Avibactam(including in combination with other drugs)		1	Antibiotic	Aug-24		
Red	Axicabtagene ciloleucel		1,6	Refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	Jul-23		NICE TA895
Red	Axitinib		1,6	In line with positive NICE TAs	Oct-24		Axitinib NICE information
Red	Azacitidine		1,6	Myeloid leukaemia (Acute), Myelodysplastic syndromes. Chronic or Acute myelomonocytic leukaemia	May-24		
Red	Aztreonam		1,6				
Red	Aztreonam + avibactam		1	Antibiotic	Nov-24		
Red	Bacillus Calmette-Guerin	OncoTICE®	1,6	Bladder instillation			
Red	Baricitinib		1,6	In line with positive NICE TA recommendations	Dec-23		Baricitinib NICE information
Red	Baricitinib (dual classification)		1,3	Adults and children COVID-19 Treatment	Jun-23	Oct-25	NICE NG191
Red	Basiliximab		1,6	Renal transplantation (immunosuppressive therapy)	Jun-24		
Red	Bedaquiline		1,6	Tuberculosis	Jun-24		
Red	Bee Venom (Alutard Bee Venom®)		1,6	Allergy Immunotherapy	Jun-24		

Red	Belantamab mafodotin		1,6	In line with positive NICE TA recommendations	Jun-24		Belantamab mafodotin NICE Information
Red	Belatacept		1,6	Prophylaxis of graft rejection in adult recipients of a renal transplant	Jun-24		
Red	Belimumab		1,6	In line with positive NICE TA recommendations	Jun-24		Belimumab NICE information
Red	Belumosudil		1,6	In line with positive NICE TA recommendations	Feb-24		Belumosudil NICE information
Red	Belzutifan		6	In line with positive NICE TA recommendations	Jun-23		Belzutifan NICE Information
Red	Bendamustine		1,6	Chronic lymphocytic leukaemia, multiple myeloma	Jun-24		
Red	Benperidol		1	Antipsychotic	Feb-24		
Red	Benralizumab		1,6	In line with positive NICE TA recommendations	Jun-24		Benralizumab NICE Information
Red	Benzylpenicillin benzathine		1,6		Jun-24		
Red	Beractant		1,6	Pulmonary surfactants	Jun-24		
Red	Berotrastat		1,6	NHSE commissioned.	Jun-24		
Red	Beta Interferon		1,6		Jun-24		
Red	Betaine		1,6	Drugs used in metabolic disorders	Jun-24		
Red	Betamethasone injection		1,6	Status asthmaticus, shock from surgery/trauma, acute adrenal crisis, soft tissue lesions	Jun-24		
Red	Betula verrucosa		1	Treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen	Sep-25		NICE TA1087
Red	Bevacizumab		1,6	In line with positive NICE TA recommendations	Jun-23		Bevacizumab NICE information
Red	Bexarotene		1,6	Cutaneous T-cell lymphoma (CTCL) - skin manifestations of advanced stage	Jun-24		
Red	Bezlotoxumab		1,6	Prevention of recurrence of Clostridium difficile infection (CDI)	Jun-24		
Red	Bictegravir/emtricitabine/tenofovir alafenamide		1,6	Adults infected with human immunodeficiency virus-1 (HIV-1)	Jun-24		

Red	Bimekizumab		1	In line with positive NICE TA recommendations	Nov-23		Bimekizumab NICE information
Red	Binimetinib		1,6	In line with positive NICE TA recommendations			Binimetnib NICE information
Red	Birch bark extract	Filsuvez®	1,6	Treating epidermolysis bullosa	Oct-23		
Red	Bivalirudin		1,6				
Red	Bleomycin		1,6				
Red	Blinatumomab		1,6	In line with positive NICE TA recommendations	May-25		Blinatumomab NICE Information
Red	Bortezomib		1	In line with positive NICE TA recommendations	Sep-23		Bortezomib NICE information
Red	Bosentan		1	Pulmonary arterial hypertension & Systemic sclerosis with ongoing digital ulcer disease	Oct-23		
Red	Bosutinib		1,6	Chronic myeloid leukaemia	Jun-24		
Red	Botulinum toxin type A		1	In line with positive NICE TA recommendations	Sep-23		Botulinum toxin type A NICE information
Red	Brentuximab vedotin		1,6	in line with positive NICE TA Recommendations	Jun-25		Brentuximab+vedotin NICE Information
Red	Brexucabtagene autoleucel		1,6	Refractory B-cell acute lymphoblastic leukaemia	Jul-23		NICE TA893
Red	Brigatinib		1,6	Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	Jun-24		
Red	Brodalumab		1,6	Psoriasis (moderate to severe plaque) in adult patients who are candidates for systemic therapy.	Jun-24		
Red	Brolucizumab		1,6	Neovascular (wet) age-related macular degeneration (AMD)	Jun-24		
Red	Bromfenac		1,6	Ocular inflammation following cataract extraction in adults.	Jun-24		
Red	Budesonide 4mg m/r capsule	Kinpeygo®	1,6	Targeted-release budesonide for treating primary IgA nephropathy	Mar-26		NICE TA1128
Red	Budesonide orodispersible tablet	Jorveza®	1,6	In line with positive NICE TA recommendations	Jun-24		Budesonide Orodispersible tablet NICE information

Red	Bulevirtide		1,6	Treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adults with compensated liver disease	Jul-23		NICE TA896
Red	Bupivacaine		1,6	Local and surgical anaesthesia	Jun-24		
Red	Buprenorphine		1	Opioid dependence	Feb-26		
Red	Buprenorphine/Naloxone		1	Opioid drug dependence	Nov-25		Buprenorphine/naloxone NICE information
Red	Burosumab		1,6	In line with positive NICE TA recommendations	Oct-24		Burosumab NICE Information
Red	Buserelin		1,6	Infertility	Jul-24		
Red	Busulfan		1,6		Jul-24		
Red	C1 Esterase inhibitor		1,6	Acute hereditary angioedema	Jul-24		
Red	Cabazitaxel		1,6	In line with positive NICE TA recommendations	Jul-24		Cabazitaxel NICE Information
Red	Cabotegravir		1,6	In line with positive NICE TA recommendations	Jul-24		Cabotegravir NICE information
Red	Cabozantinib(including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Jul-24		Cabozantinib NICE Information
Red	Calcitonin (salmon)		1,6	Hypercalcaemia, Pagets disease,Bone pain in neoplastic disease, postmenopausal osteoporosis	Jul-24		
Red	Calcium Chloride injection		1,6	Emergency Treatment of Poisoning (calcium channel blockers or systemic effects of hydrofluoric acid)	Jul-24		
Red	Calcium Folate		1,6		Jul-24		
Red	Calcium Gluconate		1,6		Jul-24		
Red	Calcium Polystyrene Sulfonate		1	All licensed indications	Feb-26		
Red	Canakinumab		1,6	NHSE Commissioned	Jul-24		
Red	Cannabidiol		1,6	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Red	Cannabinoids		1	In line with positive NICE TA recommendations	Dec-23		Cannabidiol NICE information

Red	Capecitabine		1,6	In line with positive NICE TA recommendations	Jul-24		Capecitabine NICE Information
Red	Capivasertib (in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Jun-25		Capivasertib NICE Information
Red	Caplacizumab		1,6	In line with positive NICE TA recommendations	Jul-24		Caplacizumab NICE Information
Red	Capreomycin			Tuberculosis	Aug-24		
Red	Capsaicin Patch	Qutenza®	1	Peripheral neuropathic pain	Sep-23		
Red	Carbetocin		1,6	Uterine atony and postpartum haemorrhage after Caesarian section(prevention of)	Jul-24		
Red	Carboplatin		1,6	In line with positive NICE TA recommendations	Jul-24		
Red	Carboprost		1,6	Post-partum haemorrhage	Jul-24		
Red	Carfilzomib		1,6	In line with positive NICE TA recommendations	Jul-24		
Red	Carglumic acid		1,6	Drugs used in metabolic disorders	Jul-24		
Red	Cariprazine		1	Antipsychotic	Feb-24		
Red	Carmustine		1,6	In line with positive NICE TA recommendations	Jul-24		Carmustine NICE Information
Red	Carnitine		1,6	Carnitine deficiency	Jul-24		
Red	Caspofungin		1,6	Antifungal	Jul-24		
Red	Catridecacog		1,6	Long term prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency and treatment of breakthrough bleeding episodes during regular prophylaxis	Jul-24		
Red	Cefazolin		1,6	Treatment of skin/soft tissue infections and bone/joint infections	Jul-24		
Red	Cefepime		1,6	Treatment of infections caused by bacteria that are cefepime-sensitive	Jul-24		
Red	Cefepime + enmetazobactam		1	Antibiotic	Aug-24		
Red	Cefiderocol		1,6	Infections due to aerobic Gram-negative organisms	Jul-24		
Red	Cefixime		1	Antibacterial	Feb-24		

Red	Cefoxitin		1,6	Antibiotic	Jul-24	
Red	Ceftaroline fosamil		1,6	Infection - complicated skin and soft tissue infections (cSSTI) and community-acquired pneumonia (CAP) in adults	Jul-24	
Red	Ceftazidime (including in combination with other drugs)		1	Antibiotic	Aug-24	
Red	Ceftobiprole		1,	Antibiotic	Aug-24	
Red	Ceftolozane (including in combination with other drugs)		1,	Antibiotic	Aug-24	
Red	Cefuroxime eye drops and injections		1	Miscellaneous ophthalmic preparations	Aug-24	
Red	Cemiplimab		1,6	In line with positive NICE TA recommendations	Jul-26	Cemiplimab NICE Information
Red	Cenobamate (in children only)		7	Epilepsy	May-24	
Red	Ceritinib		1,6	In line with positive NICE TA recommendations	Aug-24	Ceritinib NICE information
Red	Certolizumab		1,6	In line with positive NICE TA recommendations	Aug-24	Certolizumab NICE Information
Red	Cetrorelix		1	Treatment of female infertility	Aug-24	
Red	Cetuximab		1,6	In line with positive NICE TA recommendations	Aug-24	Cetuximab NICE Information
Red	Chlorambucil		1		Aug-24	
Red	Chloramphenicol (oral or injectables)		1		Aug-24	
Red	Chlormethine hydrochloride		1,6		Aug-24	
Red	Chloroquine			For malaria prophylaxis is grey, for treatment of malaria and other indications is red.	Aug-24	
Red	Chlorothiazide		1,6	Unlicensed special. Used in BHNFT (paediatrics)	Aug-24	

Red	Chorionic Gonadotrophin		1,6	Infertility.	Aug-24		
Red	Cidofovir		1,6	Cytomegalovirus infection in immunocompromised patients	Aug-24		
Red	Cipaglucosidase alfa		1	In line with positive NICE TA recommendations	Sep-23		Cipaglucosidase NICE information
Red	Ciprofloxacin eye drops		1	Miscellaneous ophthalmic preparations	Aug-24		
Red	Cisplatin		1,6	In line with positive NICE TA recommendations	Aug-24		Cisplatin NICE Information
Red	Cladribine (all formulations)		1,6	In line with positive NICE TA recommendations	Aug-24		Cladribine NICE information
Red	Clobazam		1	Anxiety (severe- short-term relief)	Feb-26		
Red	Clofarabine		1,6	Acute lymphoblastic leukaemia	Aug-24		
Red	Clofazimine		1,6	Leprosy	Aug-24		
Red	Clozapine				Dec-25		
Red	Cobicistat (including combinations)		1,6	NHSE commissioned.	Aug-24		
Red	Co-careldopa intestinal gel	Duodopa®	1,6	Parkinson's Disease	Jul-23		
Red	Conestat alfa		1,6	Angioedema (hereditary)	Aug-24		
Red	Copper histidinate injections	Copper histidinate injections	1	Presymptomatic neonates with classical Menkes disease	May-26		
Red	Crisantaspace		1,6	Acute lymphoblastic leukaemia	Aug-24		
Red	Crizotinib		1,6	In line with positive NICE TA recommendations	Aug-24		Crizotinib NICE Information
Red	Crovalimab		1,6	In line with positive NICE TA recommendations	Feb-25		Crovalimab NICE Information
Red	Cyclophosphamide		1,6	Cancer chemotherapy	Aug-24		
Red	Cycloserine		1		Aug-24		
Red	Cyproheptadine		1	Emergency Treatment of Poisoning (Serotonin Syndrome)	Aug-24		
Red	Cytarabine (including in combination with other drugs)		1		Aug-24		

Red	Dabrafenib (including in combination with other drugs)		1	In line with positive NICE TA recommendations	Sep-23		Dabrafenib NICE information
Red	Dacomitinib		1,6	In line with positive NICE TA recommendations	Oct-24		Dacomitinib NICE information
Red	Dactinomycin		1,6	Paediatric cancers	Oct-24		
Red	Dalbavancin		1,6	Glycopeptide antibacterial	Oct-24		
Red	Danicopan with ravulizumab or eculizumab		1,6	In line with positive NICE TA recommendations	Nov-24		Danicopan NICE Information
Red	Dapsone (dual classification)		1	Various indications Traffic Lighted Red for all other indications not included in the Place guidance/ SCP	Nov-24		
Red	Daptomycin		1	Lipopeptide antibacterial	Oct-24		
Red	Daratumumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Sep-23		Daratumumab NICE information (also used with dexamethasone and Lenalidomide)
Red	Darcabazine		1	Melanoma,Soft-tissue sarcomas,Hodgkin's disease	Oct-24		
Red	Darolutamide (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-24		Darolutamide NICE Information
Red	Darunavir (including in combination)		1	HIV infection	Oct-24		
Red	Dasabuvir		1,6	Chronic hepatitis C	Nov-24		
Red	Dasatinib		1,6	In line with positive NICE TA recommendations	Oct-24		Dasatinib NICE information
Red	Daunorubicin		1,6	In line with positive NICE TA recommendations	Oct-24		Daunorubicin NICE Information
Red	Deferasirox		1	Iron overload	Oct-24		
Red	Deferiprone		1	Iron overload in patients with thalassaemia major	Oct-24		
Red	Delaflaxacin		1,6	Fluoroquinolone antibiotic	Apr-25		
Red	Delamanid		2	Pulmonary multi drug resistant TB	Nov-24		

Red	Delgocitinib		1,6	Treating moderate to severe chronic hand eczema	Dec-25		NICE TA1107
Red	Denosumab 120mg injection	XGEVA	1	In line with NICE TA 549 and NICE TA265	Sep-23		Denosumab NICE TA549 & TA 265 information
Red	Dequalinium chloride vaginal tablets		1	Bacterial vaginosis	Sep-23		
Red	Deucravacitinib		1,6	Treating moderate to severe plaque psoriasis	Sep-23		
Red	Deutivacaftor + tezacaftor + vanzacaftor		1,6	Cystic fibrosis	Sep-25		NICE TA1085
Red	Dexamethasone and levofloxacin eye drops		1	Prevention of infection associated with cataract surgery in adults	Sep-23		
Red	Dienogest			Endometriosis	Jul-26		
Red	Digoxin specific antibody fragments		1,6	Management of digoxin toxicity	Apr-25		
Red	Diloxanide		1,6	Antiprotozoal drugs -amoebicides	Apr-25		
Red	Dimethyl fumarate		1,6	In line with positive NICE TA recommendations	Apr-25		Dimethyl+fumarate NICE information
Red	Dinoprostone		1,6	Induction of labour	Apr-25		
Red	Dinutuximab		1,6	In line with positive NICE TA recommendations	Apr-25		Dinutuximab NICE Information
Red	Diroximel		1,6	Multiple sclerosis (MS) relapsing-remitting	Apr-25		
Red	Disodium Pamidronate		1,6	Hypercalcaemia, Paget's Disease	Apr-25		
Red	Disopyramide		1,6	All licensed indications	Mar-26		
Red	Dobutamine		1,6	Inotropic Sympathomimetics	Apr-25		
Red	Docetaxel		1,6	In line with positive NICE TA recommendations	Apr-25		Docetaxel NICE Information
Red	Dolutegravir (including combinations)		1,6	HIV	Apr-25		
Red	Doravirine (including in combination)		1,6	HIV	May-25		

Red	Dornase alfa		1,6		Jul-24		
Red	Dostarlimab		1,6	In line with positive NICE TA recommendations	May-25		Dostarlimab NICE Information
Red	Doxapram Hydrochloride		1,6	Postoperative respiratory depression/Acute respiratory failure	May-25		
Red	Doxorubicin		1,6	In line with positive NICE TA recommendations	May-25		Doxorubicin NICE Information
Red	Dronedarone		1	Atrial fibrillation			NICE TA197
Red	Droperidol		1	Prevention and treatment of postoperative nausea and vomiting	May-25		
Red	Dupilumab		1,6	In line with positive NICE TA recommendations	Jul-26		Dupilumab NICE information
Red	Durvalumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Feb-24		Durvalumab NICE information also used in combination with other drugs
Red	Eculizumab		1,6	In line with positive NICE TA recommendations	Apr-24		Eculizumab NICE Information
Red	Efanesoctocog alfa			Treatment and prophylaxis of bleeding in patients aged ≥ 2 years with severe or moderate haemophilia A ($\leq 5\%$ endogenous plasma factor VIII activity)	May-25		NICE TA1051
Red	Efavirenz (including in combination)		1,6	HIV	May-25		
Red	Efmoroctocog alfa		1,6	Used to treat bleeding disorders	May-25		
Red	Eladocagene exuparvovec		1,6	Treatment of patients aged ≥ 18 months with a clinical, molecular and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase deficiency with a severe phenotype	Dec-23		
Red	Elafibranor		1,6	for previously treated primary biliary cholangitis	Dec-24		
Red	Elbasvir-grazoprevir		1,6	In line with positive NICE TA recommendations	May-25		Elbasvir-grazoprevir NICE information
Red	Elosulfase alfa		1,6	Mucopolysaccharidosis type 4A	May-25		Elosulfase+alfa NICE Information

Red	Elranatamab		1,6	In line with positive NICE TA recommendations	Jan-25		Elranatamab NICE Information
Red	Eltrombopag olamine		1	Treating chronic immune thrombocytopenia in adults	Sep-23		NICE TA293
Red	Elvitegravir (including combinations)		1,6	HIV	May-25		
Red	Emicizumab		1,6	Prophylaxis of haemorrhage in haemophilia A	May-25		
Red	Emtricitabine (including combinations)		1,6	HIV	May-25		
Red	Encorafenib		1,6	In line with positive NICE TA recommendations	May-25		Encorafenib NICE Information
Red	Enfortumab vedotin (including combinations)		1,6	In line with positive NICE TA recommendations	Oct-25		Enfortumab+vedotin NICE Information
Red	Enfuvirtide		1,6	HIV	May-25		
Red	Entecavir		1,6	In line with recommended NICE TA's	Jun-25		Entecavir NICE Information
Red	Entrectinib		1,6	In line with recommended NICE TA's	Jun-25		Entrectinib NICE information
Red	Enzalutamide		1	In line with positive NICE TA recommendations	Sep-23		Enzalutamide NICE information
Red	Epcoritamab		1,6	In line with positive NICE TA recommendations	Apr-24		Epcoritamab NICE Information
Red	Ephedrine 30mg/10ml and 30mg/ml injection		1	Vasoconstrictor Sympathomimetics	Jun-25		
Red	Epirubicin		1	Cancer - breast (Advanced or metastatic) Cancer - Colorectal (metastatic)	Jun-25		
Red	Eplontersen		1,6	In line with positive NICE TA recommendations	Jan-25		Eplontersen NICE Information
Red	Epoetin Alfa		1	Renal anaemia or anaemia associated with chemotherapy	Jun-25		Epoetin alfa NICE information
Red	Epoetin Beta		1	Renal anaemia or anaemia associated with chemotherapy	Jun-25		Epoetin Beta NICE information
Red	Epoetin Zeta		1	Renal anaemia or anaemia associated with chemotherapy	Jun-25		-

Red	Epoprostenol		1,6	pulmonary arterial hypertension, to prevent blood clotting during kidney dialysis in emergency situations	Jul-25		
Red	Eptacog alfa (activated)	(NovoSeven®)	1,6	Treatment of severe postpartum haemorrhage	Jun-25		
Red	Eptacog beta	(Cevenfacta®) (activated)	1,6	Treatment of bleeding episodes and for the prevention of bleeding: in patients with congenital haemophilia	Jun-25		
Red	Eptifibatide		1	In line with recommended NICE TA's	Jun-25		Eptifibatide NICE information
Red	Eptinezumab		1	Migraine	Sep-23		NICE TA871
Red	Eravacycline	(Xerava®)	1	Complicated intra-abdominal infections in adults	Jun-25		
Red	Erdafitinib		1,6	In line with recommended NICE TA's	Jun-25		Erdafitinib NICE Information
Red	Erenumab		1,3	Migraines in adults			NICE TA682
Red	Ergometrine		1	Postpartum haemorrhage caused by uterine atony	Jun-25		
Red	Eribulin		1,6	In line with recommended NICE TA's	Jun-25		Eribulin NICE information
Red	Erlotinib		1	In line with positive NICE TA recommendations	Sep-23		Erlotinib NICE information
Red	Ertapenem		1	Carbapenems	Jun-25		
Red	Esketamine solution for injection/infusion		1	Anaesthesia and pain relief (analgesia)	Jun-25		
Red	Eslicarbazepine (in children only)		7	Epilepsy	May-24		
Red	Esmolol	(Brevibloc®)	1	Beta-adrenoceptor blocking drugs	Jun-25		
Red	Etanercept		1,6	In line with recommended NICE TA's	Jul-25		Etanercept NICE information
Red	Etelcalcetide		1	In line with recommended NICE TA's	Jul-25		Etelcalcetide NICE information
Red	Etoposide		1	In line with recommended NICE TA's	Jul-25		Etoposide NICE information
Red	Etranacogene dezaparvovec		1,6	Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B	Oct-24		
Red	Etrasimod		1,6	moderately to severely active ulcerative colitis in people aged 16 and over	Jun-24		
Red	Etravirine		1,6	HIV infection.	Jul-25		

Red	European Viper Venom Antiserum		1	European Adder bite	Jul-25		
Red	Everolimus		1	In line with positive NICE TA recommendations	Sep-23		Everolimus NICE information
Red	Evolocumab		1,6	In line with recommended NICE TA's	Jul-25		Evolocumab NICE information
Red	Ex vivo expanded autologous human corneal epithelial cells containing stem cells	(Holoclar®)	1,6	In line with recommended NICE TA's	Jul-25		Holoclar NICE information
Red	Exagamglogene autotemcel		1,6	In line with positive NICE TA recommendations	Oct-24		Exagamglogene+autotemcel NICE Information
Red	Ezetimibe in children		7	Statin	Feb-24		
Red	Factor VIIa, Factor VIII, Factor IX, Factor XIII		1,6	Haemorrhage in patients with haemophilia A or B with antibodies to factors VIII or IX, acquired haemophilia, factor VII deficiency, or Glanzmann's thrombasthenia	Jul-25		
Red	Faricimab		1,6	In line with positive NICE TA recommendations	Oct-24		Faricimab NICE Information
Red	Fedratinib		1,6	In line with recommended NICE TA's	Jul-25		Fedratinib NICE information
Red	Felbamate		1	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Red	Fenfluramine		1,6	In line with positive NICE TA recommendations	May-25		Fenfluramine NICE Information
Red	Ferric carboxymaltose		1	Iron deficiency when oral iron preparations are ineffective or cannot be used.	Jul-25		
Red	Fezolinetant		1,6	Treating moderate to severe vasomotor symptoms associated with menopause	May-26		NICE TA 1143
Red	Fibrin sealants		1	Treatment and prophylaxis of haemorrhage	Jul-25		
Red	Fibrinogen		1,6	As per BCSH guidelines for specialist indications	Jul-25		
Red	Filgotinib		1	In line with recommended NICE TA's	Jul-25		Filgotinib NICE information
Red	Filgrastim		1	Neutropenia	Jul-25		
Red	Fingolimod		1,6	In line with recommended NICE TA's	Jul-25		Fingolimod NICE information

Red	Fludarabine		1	In line with positive NICE TA recommendations	Sep-23		Fludarabine NICE information
Red	Fluocinolone acetonide		1,6	Chronic diabetic macular oedema	Apr-24		
Red	Fluocinolone acetonide intravitreal implant	(Iluvien®)	1	In line with recommended NICE TA's	Jul-25		Fluocinolone acetonide intravitreal implant NICE information
Red	Fluoride tablets		6	Dental indications	Sep-23		
Red	Follitropin alfa, beta, delta & Follitropin alfa/lutropin alfa		1	IVF	Jul-25		
Red	Fomepizole		1	Emergency Treatment of Poisoning (ethylene glycol or methanol poisoning)	Jul-25		
Red	Fondaparinux		1	Acute coronary syndromes, NSTEMI, angina	Jul-25		
Red	Fosamprenavir		1,6	HIV infection.	Jul-25		
Red	Fosaprepitant		1	Chemotherapy-associated nausea and vomiting	Aug-25		
Red	Foslevodopa–foscarnid opa		1,6	Advanced Parkinson's with motor symptoms	Feb-24		NICE Information
Red	Fostamatinib		1	Treating refractory chronic immune thrombocytopenia	Aug-25		NICE TA 835
Red	Fostemsavir		1,6	HIV in combination with other anti-retroviral drugs	Aug-25		
Red	Fremanezumab		1	As per licenced appropriate NICE TA	Sep-23		Fremanezumab NICE information
Red	Fruquintinib		1,6	Previously treated metastatic colorectal cancer	Aug-25		NICE TA 1079
Red	Fulvestrant		1	In line with positive NICE TA recommendations	Sep-23		Fulvestrant NICE information
Red	Futibatinib		1,6	Treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy	Jan-26		Futibatinib NICE Information

Red	Galcanezumab		1	Migraine prevention	Aug-25		NICE TA659
Red	Galsulfase		1,6	Mucopolysaccharidosis	Aug-25		
Red	Ganciclovir eye drops		1,6	All licensed indications	Mar-26		
Red	Garadacimab		1,6	Preventing recurrent attacks of hereditary angioedema in people 12 years and over	Nov-25		NICE TA1101
Red	Gefitinib		1	In line with positive NICE TA recommendations	Sep-23		Gefitinib NICE information
Red	Gelatin	(Gelaspan®)	1,5	Plasma substitute	Apr-26		
Red	Gemcitabine		1	In line with positive NICE TA recommendations	Sep-23		Gemcitabine NICE information
Red	Gemtuzumab		1,6	Untreated acute myeloid leukaemia (AML)	Aug-25		NICE TA545
Red	Gilteritinib		1,6	Treatment of relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.	Aug-25		NICE TA642
Red	Givinostat		1,6	Treating Duchenne muscular dystrophy in people 6 years and over	Jul-26		NICE TA 1157
Red	Glatiramer		1,6	Multiple Sclerosis	Aug-25		NICE TA527
Red	Glecaprevir/Pibrentasvir		1,6	Chronic hepatitis C	Aug-25		NICE TA499
Red	Glibenclamide suspension	Amglidia®	1	Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.	May-26		
Red	Glofitamab		1,6	In line with positive NICE TA recommendations	Nov-23		Glofitamab NICE Information
Red	Glucarpidase		1,6	To reduce toxic plasma methotrexate concentration in adults and children (aged ≥28 days) with delayed methotrexate elimination	Dec-23		
Red	Golimumab		1	In line with recommended NICE TAs	Aug-25		Golimumab NICE information
Red	Green Tea Leaves extract ointment (Camellia sinensis)		1,6	Warts - genital and perianal	Jul-24		
Red	Guselkumab		1,6	In line with positive NICE TA recommendations	Aug-25		Guselkumab NICE Information

Red	Human coagulation factor VIII, human Von Willebrand factor		1,6	Haemophilia A and Von Willebrand disease- prevention and treatment of bleeding	Sep-25		
Red	Human coagulation factor X		1,6	Prophylaxis of bleeding in patients with hereditary factor X deficiency	Sep-25		
Red	Human hepatitis B immunoglobulin		1	All licenced indications	Sep-25		
Red	Human Menopausal Gonadotrophins (Menotrophin)		1	All licensed indications	Sep-25		
Red	Human normal immunoglobulin		1,6	Multiple indications	Sep-25		Immunoglobulin supporting information
Red	Hybrid closed loop systems		1,6	Managing blood glucose levels in type 1 diabetes	Feb-24		
Red	Hydroxocobalamin (dual traffic light)		1	Emergency Treatment of Poisoning (cyanide)	Sep-25		
Red	Hydroxycarbamide		1	All licensed indications	Sep-25		
Red	Ibrutinib		1,6	In line with positive NICE TA recommendations	Oct-23		Ibrutinib NICE information
Red	Icatibant		1,6	Acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency	Sep-25		
Red	Idarubicin		1	Acute non-lymphocytic leukaemia, advanced breast cancer. Acute myeloid leukaemia in children , in combination with cytarabine, for remission induction.	Sep-25		
Red	Idarucizumab		1	Rapid reversal of anticoagulant effect of dabigatran	Sep-25		
Red	Idebenone		1,6	Visual impairment in patients with Leber's Hereditary Optic Neuropathy (LHON)	Sep-25		NICE TA1093
Red	Idelalisib		1	In line with positive NICE TA recommendations	Oct-23		Idelalisib NICE information
Red	Idursulfase		1,6	Hunter syndrome (Mucopolysaccharidosis II)	Sep-25		
Red	Iloprost		1	All licensed indications	Sep-25		

Red	Imatinib		1,6	In line with positive NICE TA recommendations	Sep-25		Imatinib NICE information
Red	Imiglucerase		1,6	Drugs used in metabolic disorders/Gauchers disease	Sep-25		
Red	Imlifidase		1,6	In line with positive NICE TA recommendations	Sep-25		Imlifidase NICE information
Red	Infliximab (including biosimilar)		1,6	In line with positive NICE TA recommendations	Sep-25		Infliximab NICE information
Red	Inosine pranobex		1	Herpes simplex	Sep-25		
Red	Inotersen		1,6	In line with positive NICE recommendations	Sep-25		Inotersen NICE information
Red	Interferon Alfa, Beta 1a & 1b,		1,6	In line with positive NICE TA recommendations	Sep-25		Interferon NICE information
Red	Ipilimumab		1,6	In line with positive NICE TA recommendations	Sep-25		Ipilimumab NICE information
Red	Iptacopan		1,6	Paroxysmal nocturnal haemoglobinuria	Oct-24		Iptacopan NICE Information
Red	Isatuximab(including in combination)		1,6	In line with positive NICE TA recommendations	Sep-25		Isatuximab NICE information
Red	Isavuconazole		1,6	Invasive aspergillosis. Mucormycosis	Sep-25		
Red	Isocarboxazid		1	Depressive illness	Sep-25		
Red	Isoprenaline Sulfate		1	Inotropic Sympathomimetics	Sep-25		
Red	Isosorbide dinitrate injection		1,5	Emergency Treatment of Poisoning (hypertension)	Apr-26		
Red	Isotretinoin		1	Acne	Sep-25		
Red	ITULAZAX 12 SQ-Bet		7	Moderate-to-severe allergic rhinitis and/or conjunctivitis allergen extract of pollen from white birch	Sep-25		NICE TA1087
Red	IV nutrition products		1,5	Intravenous nutrition	Apr-26		
Red	Ivacaftor–tezacaftor–el exacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor			In line with positive NICE TA recommendations	Oct-24		NICE TA988

Red	Ivermectin 3mg tablets (dual traffic light status)		1	Red Traffic Light Status for all other indications Green for scabies treatment	Nov-24		
Red	Ivosidenib(including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Feb-24		Ivosidenib NICE information
Red	Ixazomib		1,6	In line with positive NICE TA recommendations	Oct-25		Ixazomib NICE information
Red	Ixekizumab		1	In line with positive NICE TA recommendations	Oct-25		Ixekizumab NICE information
Red	Ketamine		1,6	All licensed indications	Mar-26		Ketamine BNF Information
Red	Ketoconazole tablets		1	Cushing's syndrome	Oct-23		
Red	Lamivudine		1	For all indications	Oct-25		
Red	Lanadelumab		1,6	In line with positive NICE TA recommendations	Oct-25		Lanadelumab NICE information
Red	Landirolol hydrochloride		1,5	Supraventricular tachycardia and for the rapid control of ventricular rate	Apr-23		
Red	Lanreotide		1,6	All licensed indications	Mar-26		Lanreotide BNF Information
Red	Lanthanum		1	In line with NICE guidance	Oct-25		Lanthanum NICE information
Red	Lapatinib		1,6	In line with positive NICE TA recommendations	Oct-25		Lapatinib NICE information
Red	Laronidase		1,6	Mucopolysaccharidosis	Oct-25		
Red	Larotrectinib sulphate		1,6	In line with positive NICE TA recommendations	Oct-23		Larotrectinib NICE information
Red	Lebrikizumab		1,6	In line with positive NICE TAs	Aug-24		Lebrikizumab NICE Information
Red	Ledipasvi/Sofosbuvir		1,6	Hepatitis C	Oct-25		
Red	Lenacapavir		1,6	HIV infection	Sep-23		
Red	Lenalidomide		1,6	In line with positive NICE TA recommendations	Oct-25		Lenalidomide NICE information
Red	Leniolisib		1,6	Treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over	May-25		NICE HST33
Red	Lenograstim		1	All licensed indications	Oct-25		
Red	Lenvatinib		1	In line with positive NICE TA recommendations	Sep-23		Lenvatinib NICE information

Red	Letermovir		1,6	In line with positive NICE TA recommendations	Oct-25		Letermovir NICE information
Red	Levocarnitine		1	All licensed indications	Oct-25		Lenograstim BNF Information
Red	Levodopa + carbidopa + entacapone	Lecigon®	1,6	Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results	Dec-24		
Red	Levofloxacin- Infusion, solution for infusion, nebuliser liquid & eye drops		1,6	All licensed indications	Mar-26		Levofloxacin BNF Information
Red	Levothyroxine injection		1	Myxoedema coma and hypothyroidism in patients where oral therapy is not feasible, particularly due to difficulties in swallowing or malabsorption	Dec-23		
Red	Linezolid Traffic Lighted Red only in Barnsley, Doncaster & Sheffield (Traffic Lighted Green in Rotherham)			oxazolidinone antibacterial	Jul-26		
Red	Linzagolix		1	In line with positive NICE TA recommendations	Jul-25		Linzagolix NICE Information
Red	Lipegfilgrastim		1	All licensed indications	Oct-25		
Red	Liraglutide	Saxenda®	1,6	Weight loss	Oct-23		NICE TA664
Red	Lisocabtagene maraleucel		1,6	In line with positive NICE TA recommendations	May-25		Lisocabtagene+maraleucel NICE Information
Red	Lisocabtagene maraleucel		1,6	treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment	Jul-26		NICE TA1159

Red	Lomitapide		1	An inhibitor of microsomal triglyceride transfer protein (MTP)	Oct-23		
Red	Lomustine		1	All licensed indications	Oct-25		
Red	Loncastuximab tesirine		1,6	In line with positive NICE TA recommendations	Feb-24		Loncastuximab+tesirine NICE information
Red	Lopinavir/Ritonavir		1	All licensed indications	Oct-25		
Red	Lorlatinib		1,6	In line with positive NICE TA recommendations	Sep-23		Lorlatinib NICE information
Red	Loteprednol eye drops		1	Corticosteroid eye drops	May-26		
Red	L-Tryptophan		1,5	Adults with treatment-resistant depression following unsuccessful trial of standard antidepressants and as an adjunct to other anti-depressant medications	May-24		
Red	Lumacaftor/Ivacaftor		1,6	Treatment for cystic fibrosis	Oct-24		Lumacaftor/Ivacaftor NICE Information
Red	Lumasiran		1,6	Treatment of primary hyperoxaluria type 1 in all age groups	Sep-23		
Red	Lurasidone		1	All licensed indications	Oct-25		
Red	Lusutrombopag		1	In line with positive NICE TA recommendations	Oct-25		Lusutrombopag NICE information
Red	Macitentan		1,6	All licensed indications	Oct-25		
Red	Magnesium carbonate/Anhydrous citric acid			Bowel cleansing prior to bowel endoscopy, radiology, or colonic surgery	Jun-26		
Red	Mannitol		1,6	In line with positive NICE TA recommendations	Oct-25		Mannitol NICE information
Red	Maraviroc		1,6	All licensed indications	Oct-25		
Red	Maribavir		1,6	In line with positive NICE TA recommendations	Oct-25		Maribavir NICE information
Red	Marstacimab		1	Routine prophylaxis of bleeding episodes in patients with haemophilia	Aug-25		NICE TA1073
Red	Mavacamten		1,6	Treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3	Oct-23		NICE TA913

Red	Mecasermin		1	All licensed indications	Oct-25		
Red	Mepacrine		1	All licensed indications	Oct-25		
Red	Mepolizumab		1,6	treating severe eosinophilic asthma	Oct-25		NICE TA671
Red	Mercaptamine		1,6	All licensed indications	Oct-25		
Red	Meropenem		1	All licensed indications	Oct-25		
Red	Mesna		1	All licensed indications	Oct-25		
Red	Metaraminol		1	Acute hypotension	Jul-26		Metaraminol Information
Red	Methoxyflurane		1	All licensed indications	Oct-25		
Red	Methoxypsoralen (Also known as methoxsalen)		1	Dermatology specialist only	Jul-26		
Red	Methsuximide		1	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Red	Methyl-5-Aminolevulinate	Metvix®	1	Actinic keratoses, basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease)	Jul-26		Photodamage NICE Information
Red	Metreleptin		1,6	In line with NICE recommendations	Oct-25		Metreleptin NICE information
Red	Metyrapone		1,6	Cushing's syndrome	Jun-24		
Red	Mexiletine		1,6	All licensed indications	Oct-25		Mexiletine NICE information
Red	Midostaurin		1,6	In line with positive NICE TA recommendations	Oct-25		Midostaurin NICE information
Red	Mifamurtide		1,6	In line with positive NICE TA recommendations	Oct-25		Mifamurtide NICE information
Red	mifepristone (includes in combination)		1	All licensed indications	Oct-25		
Red	Migalastat		1,6	In line with NICE recommendations	Oct-25		Migalastat NICE information
Red	Miglustat		1	In line with positive NICE TA recommendations	Sep-23		Miglustat information
Red	Mirikizumab		1,6	In line with positive NICE TA recommendations	Aug-25		Mirikizumab NICE Information
Red	Misoprostol (includes in combination)(multiple traffic light classifications)		1	Induction of labour or miscarriage or abortion	Oct-25		

Red	Mitomycin		1	All licensed indications	Oct-25		
Red	Mitotane		1	All licensed indications	Oct-25		
Red	Mitoxantrone		1	All licensed indications	Oct-25		
Red	Mogamulizumab		1,6	In line with positive NICE TA recommendations	Oct-25		Mogamulizumab NICE information
Red	Molnupiravir		1	Treating COVID-19	May-25		NICE TA1056
Red	Momelotinib		1,6	Myelofibrosis-related splenomegaly or symptoms	May-24		
Red	Morphine Sulphate 100 microgram/ml oral solution		1	Opioid	Oct-23		
Red	Mycophenolate (dual traffic light classification)		1	Red for all other indications and TLS Amber for shared care protocols	Aug-24		
Red	Natalizumab		1,6	In line with positive NICE TA recommendations	Nov-23		Natalizumab NICE information
Red	Nelarabine		1,6	T-cell acute lymphoblastic leukaemia, T-cell lymphoblastic lymphoma	Jul-26		Nelarabine information
Red	Nelfinavir		1,5,6	HIV	Oct-25		
Red	Nemolizumab		1,6	Moderate to severe atopic dermatitis in people 12 years and over	Aug-25		NICE TA1077
Red	Nepafenac		1	All licensed indications	Oct-25		
Red	Neratinib		1,6	In line with positive NICE TA recommendations	Oct-25		Neratinib NICE information
Red	Nevirapine		1,6	All licensed indications	Oct-25		
Red	Nilotinib		1,6	In line with positive NICE TA recommendations	Oct-25		Nilotinib NICE information
Red	Nimodipine		1	All licensed indications	Oct-25		
Red	Nintedanib		1,6	In line with positive NICE TA recommendations	Oct-25		Nintedanib NICE information
Red	Niraparib		1,6	In line with positive NICE TA recommendations	Mar-26		Niraparib NICE Information
Red	Nirmatrelvir plus Ritonavir	Paxlovid®	1,3	COVID-19 Treatment	Jun-23		

Red	Nirmatrelvir plus ritonavir and tocilizumab		1,5	for treating COVID-19	Apr-26		
Red	Nirsevimab		1,6	Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season	Nov-25		
Red	Nitisinone		1,6	All licensed indications	Oct-25		
Red	Nivolumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Feb-24		Nivolumab NICE Information
Red	Noradrenaline		1	All licensed indications	Oct-25		
Red	Nusinersen (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25		Nusinersen NICE information
Red	Obecabtagene autoleucel		1,6	Relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in line with positive NICE TA	Jan-26		Obecabtagene autoleucel NICE Information
Red	Obeticholic acid		1,6	In line with positive NICE TA recommendations	Oct-25		Obeticholic acid NICE information
Red	Obinutuzumab		1,6	In line with positive NICE TA recommendations	Oct-25		Obinutuzumab NICE information
Red	Ocrelizumab		1,6	In line with positive NICE TA recommendations	Oct-25		Ocrelizumab NICE information
Red	Ofatumumab		1	In line with positive NICE TA recommendations	Nov-23		Ofatumumab NICE information
Red	Olaparib (can be given with bevacizumab & abiraterone)		1,6	In line with positive NICE TA recommendations	Sep-23		Olaparib NICE information
Red	Omalizumab		1,6	In line with positive NICE TA recommendations	Oct-25		Omalizumab NICE information

Red	Ombitasvir, paritaprevir and ritonavir		1,6	In line with positive NICE TA recommendations	Oct-25		Ombitasvir/paritaprevir/ritonavir NICE information
Red	Osimertinib		1,6	In line with positive NICE TA recommendations	Apr-25		Osimertinib NICE Information
Red	Oxaliplatin		1	In line with positive NICE TA recommendations	Oct-25		Oxaliplatin NICE information
Red	Oxybutynin intravesical solution		6	Indicated for the suppression of neurogenic detrusor overactivity (NDO) in children from 6 years of age and adults, who are managing bladder emptying by clean intermittent catheterisation, not adequately managed with oral anticholinergics.	Aug-24		
Red	Oxytocin (includes in combination)		1	All licensed indications	Oct-25		
Red	Ozanimod		1	In line with positive NICE TA recommendations	Nov-23		Ozanimod NICE information
Red	Paclitaxel		1,6	In line with positive NICE TA recommendations	Oct-25		Paclitaxel NICE information
Red	Palbociclib		1,6	In line with positive NICE TA recommendations	Oct-25		Palbociclib NICE information
Red	Palonosetron		1,6	All licensed indications	Oct-25		
Red	Panitumumab		1,6	In line with positive NICE TA recommendations	Dec-23		Panitumumab NICE information
Red	Panobinostat		1,6	In line with positive NICE TA recommendations	Oct-25		Panobinostat NICE information
Red	Paracetamol + ibuprofen solution for infusion		1	Use in adults for the short-term symptomatic treatment of acute moderate pain and the reduction of fever, where an intravenous route of administration is considered clinically necessary and/or when other routes of administration are not possible	Feb-24		
Red	Paraldehyde		1	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Red	Paricalcitol		1,6	All licensed indications	Oct-25		
Red	Pasireotide		1,6	All licensed indications	Oct-25		
Red	Patiromer		1	In line with positive NICE TA recommendations	Oct-25		Patiromer NICE information
Red	Pazopanib		1,6	In line with positive NICE TA recommendations	Oct-25		Pazopanib NICE information
Red	Pegaspargase		1,6	In line with positive NICE TA recommendations	Oct-25		Pegaspargase NICE information
Red	Pegfilgrastim (including biosimilars)		1	All licensed indications	Oct-25		
Red	Peginterferon (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25		Peginterferon NICE information
Red	Pegunigalsidase alfa		1,6	Fabry disease	Nov-23		NICE Pegunigalsidase+alfa information
Red	Pegvisomant		1,6	All licensed indications	Oct-25		
Red	Pegzilarginase		1,5	In line with positive NICE TA recommendations	Apr-26		Pegzilarginase NICE information
Red	Pembrolizumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Sep-23		Pembrolizumab NICE information
Red	Pemetrexed		1,6	In line with positive NICE TA recommendations	Oct-25		Pemetrexed NICE information
Red	Pemigatinib		1,6	In line with positive NICE TA recommendations	Oct-25		Pemigatinib NICE information
Red	Pentamidine		1	All licensed indications	Oct-25		
Red	Pentosan		1	In line with positive NICE TA recommendations	Oct-25		Pentosan NICE information
Red	Pentostatin		1	Hairy cell leukaemia	Oct-25		
Red	Pertuzumab (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25		Pertuzumab NICE information

Red	Phenylephrine + ketorolac		1	Use in adults for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery	Aug-24		
Red	Phenylephrine injection		1	For all indications. See red & grey lists	Oct-25		
Red	Pirfenidone		1,6	In line with positive NICE TA recommendations	Oct-25		Pirfenidone NICE information
Red	Pitolisant (dual classification)		1	Narcolepsy. See also Grey for other indications	Dec-25		Pitolisant NICE information
Red	Plasma-Lyte		1	Infusion - for use in adults, older patients and adolescents (age 12 years and over) for fluid replacement, as intraoperative fluid replacement, in haemorrhagic shock and clinical conditions requiring rapid blood transfusions, and in mild to moderate metabolic acidosis, also in case of lactate metabolism impairment.	Jul-26		Intravenous fluid therapy in adults in hospital
Red	Plerixafor		1,6	All licensed Indications	Oct-25		
Red	Polatuzumab (including in combination)		1,6	In line with positive NICE TA recommendations	Oct-25		Polatuzumab NICE information
Red	Pomalidomide		1,6	In line with positive NICE TA recommendations	Oct-25		Pomalidomide NICE information
Red	Ponatinib		1,6	In line with positive NICE TA recommendations	Oct-25		Ponatinib NICE information
Red	Ponesimod		1,6	In line with positive NICE TA recommendations	Oct-25		Ponesimod NICE information
Red	Posaconazole		1,6	All licensed indications	Oct-25		

Red	Potassium citrate modified-release tablet	Renodyra®	1	Use in adults for the treatment of patients with kidney stones and hypocitraturia, or chronic calcium oxalate stones; the treatment and prevention of recurrent uric acid lithiasis with or without calcium lithiasis and cystine lithiasis; the treatment of renal tubular acidosis with calcium nephrolithiasis	Apr-26	
Red	Pretomanid		1,6	TB in >14 year olds	Nov-24	NHS E document
Red	Procarbazine		1	All licensed indications	Oct-25	
Red	Progesterone micronised vaginal preparations (multiple traffic light classifications)		1	Supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles	May-26	Different products have different licensed indications - refer to the SPC.
Red	Protamine		1	Emergency treatment of poisoning (heparin reversal)	Oct-25	
Red	Quizartinib		1,6	For induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia	Nov-24	NICE TA1013
Red	Raltegravir		1,6	HIV	Oct-25	
Red	Ranibizumab (Branded/ biosimilar or in combination)		1,6	In line with positive NICE TA recommendations	Jun-23	Ranibizumab NICE information
Red	Rasburicase		1,6	Hyperuricaemia associated with cytotoxic drugs	Oct-25	
Red	Ravulizumab		1,6	In line with positive NICE TA recommendations	Feb-24	Ravulizumab NICE information
Red	Regorafenib		1,6	In line with positive NICE TA recommendations	Dec-23	

Red	Relugolix–estradiol–norethisterone (Dual traffic light status)	Ryeqo®	1,3	Treating symptoms of endometriosis	May-25		NICE TA1057
Red	Remdesivir (including in combination with other drugs)		1,3	Adults and children aged 12 years and older COVID-19 Treatment	Jun-23	Oct-25	Interim Clinical Commissioning Policy
Red	Reslizumab		1,6	In line with positive NICE TA recommendations	Oct-25		Reslizumab NICE information
Red	Ribavirin (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Ribavirin NICE information
Red	Ribociclib		1,6	In line with positive NICE TA recommendations	Sep-25		Ribociclib NICE Information
Red	Ribociclib (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Ribociclib NICE information
Red	Rilpivirine (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Rilpivirine NICE information
Red	Riociguat		1,6	All licensed indications	Nov-25		
Red	Ripretinib		1,6	In line with positive NICE TA recommendations	Jun-26		NICE TA 1146
Red	Risankizumab		1,6	In line with positive NICE TA recommendations	Oct-24		Risankizumab NICE Information
Red	Risdiplam		1,6	In line with positive NICE TA recommendations	Dec-23		Risdiplam NICE Information
Red	Ritlecitinib		1,6	Severe alopecia areata in people 12 years and over	May-24		
Red	Ritonavir (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Ritonavir NICE information
Red	Rituximab		1,6	In line with positive NICE TA recommendations	Dec-23		Rituximab NICE Information
Red	Romiplostim		1	In line with positive NICE TA recommendations	Nov-25		Romiplostim NICE information

Red	Romosozumab		1	In line with positive NICE TA recommendations	Nov-25		Romosozumab NICE information
Red	Ropeginterferon		1,6	All licensed indications	Nov-25		Ropeginterferon NICE TA in development
Red	Ropivacaine		1	All licensed indications	Nov-25		
Red	Roxadustat		1	In line with positive NICE TA recommendations	Nov-25		Roxadustat NICE information
Red	Rozanolixizumab		1,6	treating antibody-positive generalised myasthenia gravis	Jul-26		NICE TA 1155
Red	Rucaparib		1,6	In line with positive NICE TA recommendations	May-25		Rucaparib NICE Information
Red	Ruxolitinib		1,6	In line with positive NICE TA recommendations	Nov-23		NICE Ruxolitinib information
Red	Sacituzumab govitecan		1,6	In line with positive NICE TA recommendations	Sep-25		Sacituzumab+govitecan NICE TA
Red	Sapropterin		1,6	In line with positive NICE TA recommendations	Jul-24		Sapropterin NICE Information
Red	Sarilumab		1,6	In line with positive NICE TA recommendations	Nov-25		Sarilumab NICE information
Red	Sebelipase alfa (dual traffic light classification)		1,6	Wolman disease cross reference to Grey TLS	Feb-24		
Red	Secukinumab		1,6	In line with positive NICE TA recommendations	Feb-24		Secukinumab NICE information
Red	Selexipag		1,6	All licensed indications	Nov-25		
Red	Selinexor		1,6	In line with positive NICE TAs(including in combination with other drugs)			Selinexor NICE information
Red	Selpercatinib		1,6	In line with positive NICE TA recommendations	Sep-23		Selpercatinib NICE information
Red	Semaglutide injection (multiple Traffic Light entries for different indications)	Wegovy®	16	Reducing the risk of major adverse cardiovascular events in people with cardiovascular disease (NICE TA1152)and for managing overweight or obesity (NICE TA875) (Refer to Place Based Weight Management Pathways)	Sep-23		Semaglutide NICE information

Red	Serplulimab		1,6	Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer	Jul-26	NICE TA1167
Red	Setmelanotide		1,6	For treating obesity and hyperphagia in Bardet-Biedl syndrome	Jul-24	
Red	Sevelamer		1	All licensed indications	Dec-25	
Red	Sildenafil (For Pulmonary Arterial Hypertension)	Revatio	1,6	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also sildenafil entries for Erectile Dysfunction.	May-25	NHS England Commissioning policy, also can be found on NHSE High Cost drugs list
Red	Siponimod		1,6		Nov-25	Siponimod NICE information
Red	Sodium Chloride oral solution		1,5	Oral sodium	Apr-26	
Red	Sodium Oxybate		1,6	Narcolepsy	Dec-23	
Red	Sodium Phenylbutyrate (Dual Classification)		1,6	All licensed indications, see also grey traffic light classification listing	Nov-25	
Red	Sodium Zirconium Cyclosilicate		7	Hyperkalaemia	Jan-24	NICE TA 1148
Red	Sofosbuvir (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25	Sofosbuvir NICE information
Red	Solriamfetol		1,6	In line with positive NICE TA recommendations	Dec-23	Solriamfetol NICE Information
Red	Somapacitan		1	Somapacitan for treating growth hormone deficiency in people 3 to 17 years	Jul-25	NICE TA 1066
Red	Sorafenib		1,6	In line with positive NICE TA recommendations	Dec-23	Sorafenib NICE Information
Red	Sotatercept		1,6	treating pulmonary arterial hypertension	Jul-26	NICE TA 1161
Red	Sotorasib		1,6	In line with positive NICE TA recommendations	Nov-25	Sotorasib NICE information
Red	Sotrovimab		1,3	Adults and young people aged 12 years and over Covid-19 Treatment	Jun-23	

Red	Sparsentan		1,6	In line with positive NICE TA recommendations	Sep-25		Sparsentan NICE Information
Red	Spesolimab		1,3,6	Spesolimab for treating generalised pustular psoriasis flares	Jul-25		NICE TA 1070
Red	Streptomycin		1	All licensed indications	Nov-25		
Red	Streptozocin		1	All licensed indications	Nov-25		
Red	Sucroferric oxyhydroxide		1,6	All licensed indications	Nov-25		
Red	Sugammadex		1	All licensed indications	Nov-25		
Red	Sunitinib		1,6	In line with positive NICE TA recommendations	Nov-25		Sunitinib NICE information
Red	Tadalafil (For Pulmonary Arterial Hypertension)	Adcirca	1,6	Patients treated for Pulmonary Arterial Hypertension, NHSE commissioned. See also Tadalafil entries for Erectile Dysfunction.	May-25		NHS England Commissioning policy, also can be found on NHSE High Cost drugs list
Red	Tafamidis (dual traffic light combination)		1,6	In line with positive NICE TA recommendations	Jul-24		Tafamidis NICE Information Also see reference to Grey traffic light status
Red	Talazoparib		1,6	In line with positive NICE TA recommendations	Feb-24		Talazoparib NICE information
Red	Talimogene laherparepvec		1,6	In line with positive NICE TA recommendations	Nov-25		Talimogene NICE information
Red	Talquetamab		1,6	Relapsed and refractory multiple myeloma in line with positive NICE TA	Jan-26		Talquetamab NICE Information
Red	Tazobactan (including in combination with other drugs)		1	Antibiotic	Aug-24		
Red	Tebentafusp		1,6	In line with positive NICE TA recommendations	Feb-25		Tebentafusp NICE Information
Red	Teclistamab		1,6	Relapsed and refractory multiple myeloma	Jun-23		Teclistamab NICE Information
Red	Tedizolid		1	All licensed indications	Nov-25		
Red	Teduglutide		1,6	In line with positive NICE TA recommendations	Nov-25		Teduglutide NICE information
Red	Temozolomide		1,6	In line with positive NICE TA recommendations	Jul-26		Temozolomide NICE Information

Red	Tenecteplase			Treating acute ischaemic stroke	Oct-24		NICE TA990
Red	Tenofovir (including in combinatin with other drugs)		1,6	HIV & also in line with positive NICE TA recommendations	Nov-25		Tenofovir NICE information
Red	Tepotinib		1,6	In line with positive NICE TA recommendations	Nov-25		Tepotinib NICE information
Red	Teriflunomide		1,6	In line with positive NICE TA recommendations	Nov-25		Teriflunomide NICE information
Red	Teriparatide		1	In line with positive NICE TA recommendations	Nov-25		Teriparatide NICE information
Red	Terlipressin		1	All licensed indications	Nov-25		
Red	Tetracosactide		1	All licensed indications	Nov-25		
Red	Tezacaftor (in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Tezacaftor NICE information
Red	Tezepelumab		1	In line with positive NICE TA recommendations	Nov-25		Tezepelumab NICE information
Red	Thalidomide		1,6	In line with positive NICE TA recommendations	Nov-25		Thalidomide NICE information
Red	Thiamine hydrochloride injection		1	Thiamine deficiency conditions	Jan-25		
Red	Thiotepa		1	All licensed indications	Nov-25		
Red	Tigecycline		1	All licensed indications	Nov-25		
Red	Tildrakizumab		1	In line with positive NICE TA recommendations	Nov-25		Tildrakizumab NICE information
Red	Tioguanine		1	All licensed indications	Nov-25		
Red	Tirofiban		1	In line with positive NICE TA recommendations	Nov-25		Tirofiban NICE information

Red	Tirzepatide weight management - patients who fulfill NICE TA 1026 AND meet NHS SY Specialist Weight Management Service referral criteria [Multiple traffic light classifications]		6	For managing overweight and obesity in patients who fulfil NICE TA1026, including those in cohort one & two who may not want or be suitable for management in primary care AND meet NHS SY SWMS referral criteria.	May-25		Tirzepatide weight management Information
Red	Tisagenlecleucel		1,6	In line with positive NICE TA recommendations	Feb-24		Tisagenlecleucel NICE information
Red	Tisotumab vedotin		1,6	treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment	Jul-26		NICE TA1164
Red	Tivozanib		1,6	In line with positive NICE TA recommendations	Nov-25		Tivozanib NICE information
Red	Tocilizumab		1,3	In line with positive NICE TAs. COVID-19 indication is for infusion only	Jun-23		Tocilizumab NICE Information
Red	Tofacitinib		1	In line with positive NICE TA recommendations	Nov-23		Tofacitinib NICE information
Red	Tolvaptan		1,6	In line with positive NICE TA recommendations	Nov-25		Tolvaptan NICE information
Red	Topotecan		1,6	In line with positive NICE TA recommendations	Feb-24		Topotecan NICE information
Red	Trabectedin		1,6	In line with positive NICE TA recommendations	Feb-24		Trabectedin NICE Information
Red	Tralokinumab		1,6	In line with positive NICE TA recommendations	Nov-25		Tralokinumab NICE information
Red	Trametinib		1	In line with positive NICE TA recommendations	Sep-23		Trametinib NICE information
Red	Trastuzumab (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Trastuzumab NICE information
Red	Treosulfan		1,6	In line with positive NICE TA recommendations	Feb-24		Treosulfan NICE information
Red	Treprostinil		1,6	All licensed indications	Nov-25		

Red	Tretinoin		1	All licensed indications	Nov-25		
Red	Trientine		1,6	All licensed indications	Nov-25		
Red	Trifluridine/Tipiracil		1,6	In line with positive NICE TAs	Feb-24		Trifluridine/Tipiracil NICE Information
Red	Ublituximab		1,6	In line with positive NICE TA recommendations	Jan-25		Ublituximab NICE Information
Red	Ulipristal acetate 5mg tablets	Esmya®	1	Fibroids	Feb-24		
Red	Upadacitinib		1,6	Crohn's disease	Jul-23		NICE TA905
Red	Upadacitinib		1,6	In line with positive NICE TA recommendations	Nov-25		Upadacitinib NICE information
Red	Ustekinumab		1,6	In line with positive NICE TA recommendations	Nov-25		Ustekinumab NICE information
Red	Vadadustat		1,6	In line with positive NICE TA recommendations	Aug-24		Vadadustat NICE Information
Red	Valganciclovir		1	All licensed indications	Nov-25		
Red	Vamorolone		1,6	In line with positive NICE TA recommendations	Feb-25		Vamorolone NICE Information
Red	Vancomycin injection		1,5		Apr-26		
Red	Vanzacaftor-tezacaftor-deutivacaftor		1,6	treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over	Sep-25		NICE TA 1085
Red	Varicella (chickenpox) vaccine	Varilrix®, Varivax®	6	Vaccine for use Prior to Immunosuppression, in Adults and Children without Immunity	Oct-23		
Red	Vasopressin		1	All licensed indications	Nov-25		
Red	Vedolizumab		1,6	In line with positive NICE TA recommendations	Feb-24		Vedolizumab NICE Information
Red	Velmanase alfa		1,6	Alpha-mannosidosis	Feb-24		
Red	Venetoclax (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Nov-25		Venetoclax NICE information
Red	Verteporfin		1	All licensed indications	Nov-25		
Red	Vinblastine		1	All licensed indications	Nov-25		
Red	Vincristine		1	All licensed indications	Dec-25		

Red	Vindesine		1	All licensed indications	Dec-25		
Red	Vinorelbine		1	All licensed indications	Dec-25		Volanesorsen NICE information
Red	Vismodegib		1,6	In line with positive NICE TA recommendations	Feb-24		Vismodegib NICE information
Red	Voclosporin		1,6	In line with positive NICE TA recommendations	Feb-24		Voclosporin NICE information
Red	Volanesorsen		1,6	In line with NICE recommendations	Dec-25		
Red	Vonicog alfa			von willebrand disease	Dec-25		Voretigene neparvovec NICE information
Red	Vorasidenib	Voranigo®	1,6	In line with positive NICE TA recommendations	Dec-25		NICE TA 1147
Red	Voretigene neparvovec		1,6	In line with positive NICE TA recommendations	Dec-25		
Red	Voriconazole		1,6	All licensed indications	Dec-25		
Red	Vutrisiran		1,6	In line with positive NICE TA recommendations	Sep-23		Vutrisiran NICE information
Red	Zanidatamab		1,6	In line with positive NICE TA recommendations	Jun-26		NICE TA 1153
Red	Zanubrutinib (including in combination with other drugs)		1,6	In line with positive NICE TA recommendations	Dec-23		Zanubrutinib NICE information
Red	Zidovudine (in combination with other retroviral drugs)		1,6	HIV	Dec-25		
Red	Zolbetuximab (including in combination)		2	Advanced gastric or gastro-oesophageal junction adenocarcinoma	Apr-25		NICE TA 1046
Red	Zoledronic acid		1	All licensed indications	Dec-25		
Red	Zuclopenthixol Acetate		1	Short term management of acute psychosis	May-25		
Amber	ACARIZAX 12 SQ-HDM		1,3	House dust mite sensitisation	May-22	Feb-27	Sublingual Immunotherapy (SCP)
Amber	Acetazolamide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Amber	Alimemazine (dual traffic light classification)	Izenal SF or Alfresed (sugary version)	1,2,3	Treatment of sleep disorders in Children (from Specialist Clinicians at Sheffield Children's NHS Foundation Trust Tertiary Sleep Service only)	Aug-24	Aug-29	SY Alimemazine SCP
Amber	Amantadine (Multiple traffic light classification)		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Apomorphine		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Azathioprine (dual Traffic Light status)		1,2 ab	In line with Place based shared care protocols, preparations within the documents. . Cross reference to Grey traffic light status for high strengths (75mg &100mg) Doncaster has a Red traffic light status - see Place based formulary for further information	Apr-24		
Amber	Brivaracetam		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Bromocriptine		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Cabergoline		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Carbamazepine		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Cenobamate (see appendix information for community pharmacy re ordering)		1,2,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Clobazam		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Clonazepam		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Amber	Co-beneldopa		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Co-careldopa		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Dalteparin		1,2,3	Various indications Traffic Lighted Red for all other indications not included in the Place guidance/ SCP Refer to Place based guidance/ SCP for further information	Nov-24		Medicines Optimisation Information
Amber	Dapsone (dual classification)		1,2,3	Various indications Traffic Lighted Red for all other indications not included in the Place guidance/ SCP	Nov-24		Medicines Optimisation Information
Amber	Denosumab 60mg Injection	(Prolia®)	1,2,3	Indications as outlined in the Shared Care Protocol. Please note 120mg strength (XGEVA) is RED.	Aug-24	Aug-29	SY Denosumab SCP
Amber	Diazepam (rectal)		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Entacapone		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Eslicarbazepine		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Ethosuximide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Finerenone		7	Chronic Kidney Disease in Type 2 Diabetes	Jun-24	Dec-25	SY Finerenone SCP
Amber	Gabapentin		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	GRAZAX 75,000 SQ-T oral lyophilisate		1,3	Grass pollen sensitisation	May-22	Feb-27	Sublingual Immunotherapy (SCP)
Amber	Hydrocortisone MR 5mg & 10mg capsules	Efmody®	1	Congenital adrenal hyperplasia	Sep-23		Link to SCP (when uploaded on website)
Amber	Lacosamide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Lamotrigine		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Amber	Levetiracetam		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Liothyronine		1,2,3	From NHS Endocrinologists only	Aug-24	Aug-29	SY Liothyronine SCP
Amber	Melatonin (Dual traffic light classification)		1,3	As per Place shared care protocols	Oct-23		Melatonin Information
Amber	Melatonin (Dual traffic light classification)		1,3	For the treatment of sleep disorders in children and young people up to 18 years (off-label use)	Dec-25	Dec-28	Refer to Place based formularies SY Children's and young peoples Melatonin SCP
Amber	Methylphenidate		1,2,3	Use as part of a comprehensive treatment programme for attention-deficit/ hyperactivity disorder in children aged ≥6 years and adults when remedial measures alone prove insufficient	Feb-24		Methylphenidate Information
Amber	Midazolam (Buccal)		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Modafinil		1,3	Refer to Place based Shared care protocol/ prescribing guidance	Nov-20	Nov-25	Modafinil Information
Amber	Mycophenolate (dual traffic light classification)		1,2,3	TLS Amber for shared care protocols and Red for all other indications Refer to SCP at Place	Aug-24		Mycophenolate Information
Amber	Opicapone		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Oxcarbazepine		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Perampanel		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Phenobarbital		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Phenytoin		1,3		Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Pramipexole		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Pregabalin		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Primidone		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults

Amber	Rasagiline		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Relugolix–estradiol–norethisterone acetate (Dual traffic light status)	Ryeqo®	3	Uterine Fibroids	Oct-24	Oct-27	SY Relugolix-estradiol-norethisterone acetate (Ryeqo®) Shared Care Protocol
Amber	Riluzole		1,3	Riluzole Shared Care Protocol(see Place formulary)	Oct-23		Riluzole Medicines Optimisation Information
Amber	Ropinirole		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Rotigotine		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Rufinamide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Safinamide		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Selegiline		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Sodium Valproate		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Stalevo® (levodopa, carbidopa and entacapone)		1,3	Parkinson's medication	Nov-21	Nov-26	Barnsley, Bassetlaw, Doncaster and Sheffield Parkinson's SCP
Amber	Stiripentol		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Topiramate		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Vigabatrin		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber	Zonisamide		1,3	Epilepsy medication	Apr-22	Apr-27	SY & Bassetlaw SCP for Epilepsy in Adults
Amber G	Alpha Tocopheryl Acetate (Vitamin E)		1,2b	Following British National Formulary (BNF) advice	Mar-26		Alpha-Tocopheryl BNF Information
Amber G	Alprostadil cream		1	Erectile dysfunction	Mar-26		

Amber G	Amantadine (multiple traffic light classification)			In Line with NICE guidance (Multiple-Sclerosis)	Feb-24		
Amber G	Atogepant		1,2b	Prevention of episodic and chronic migraine	Feb-26		Atogepant Amber G Guideline
Amber G	Dexcom One +			Continuous Glucose Monitor	Nov-24		
Amber G	Donepezil		1,2b	Mild to moderately severe dementia in Alzheimer's disease	Jun-26		SY Dementia Guidelines
Amber G	Duloxetine		1	Stress Urinary Incontinence	Sep-23		NICE NG123
Amber G	Eflornithine cream		1,2	Treatment of facial hirsutism in women	Jul-23		NICE guidance
Amber G	Fentanyl (Immediate release)		1,2b	For patients undergoing palliative care treatment as per NHSE guidance	Dec-23		NHS E Guideline
Amber G	Freestyle Libre 2+			Continuous Glucose Monitor	Nov-24		SY CGM Guidance
Amber G	Freestyle Libre Flash Glucose Monitoring System		1,2		Sep-23		SY CGM Guidance
Amber G	Galantamine		1,2b	Mild to moderately severe dementia in Alzheimer's disease	Jun-26		SY Dementia Guidelines
Amber G	Hydrocortisone oral solution		1,2a	Dual classification	Jun-24		
Amber G	Ibandronic acid		1,2b	Adjuvant therapy in early breast cancer	Feb-24		Ibandronic acid SY Guidance
Amber G	Iatanoprost/netarsudil eye drops	Roclanda®		Previously treated primary open-angle glaucoma or ocular hypertension	Feb-26		NICE TA 1009
Amber G	Memantine (also see grey entry for memantine orodispersible tablet formulation)		1,2b	Moderate to severe dementia in Alzheimer's disease	Jun-26		SY Dementia Guidelines
Amber G	Metolazone 5mg	(Xaqua®)		Oedema related to kidney disease and Congestive Heart Failure (CHF)	Feb-24		Metolazone guideline

Amber G	Progesterone 400mg soft vaginal capsules	Prometrium®	1,2b	Indicated for the prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages	Feb-26		
Amber G	Progesterone micronised vaginal preparations (multiple traffic light classifications)		1,2b	Prevention of preterm birth.	May-26		Different products have different licensed indications - refer to the SPC.
Amber G	Reboxetine		1,2a	Treatment of depression	Dec-23		
Amber G	Relugolix	Orgovyx®	1,2b	Treating hormone-sensitive prostate cancer	Jul-26		NICE TA995
Amber G	Rimegepant (Dual classification)		1,2b	Prevention of episodic migraine Also cross reference to Green classification)	Feb-26		Rimegepant Amber G Guidance
Amber G	Rivastigmine		1,2b	Mild to moderately severe dementia in Alzheimer's disease	Jun-26		SY Dementia Guidelines
Amber G	Tirzepatide type 2 diabetes		1,2b	Treating type 2 diabetes.	Dec-23		SY Tirzepatide Amber G Guidance
Green	Fluoride toothpastes (2800ppm and 5000ppm) ONLY (specialist recommendation)			High strength toothpaste (specialist recommendation) only when prescribing in line with the exceptions in the Position Statement.	May-25		SY Dental Statement
Green	5 Fluorouracil and salicylic acid 5FU-SA	Actikerall		Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance
Green	Acetic acid 2%			Acute otitis externa	Mar-26		
Green	Aciclovir 3% eye ointment			Herpes Simplex infection	Aug-24		
Green	Adapalene plus benzoyl peroxide 0.1%/2.5%.			Acne	Mar-26		
Green	Adrenaline (Dual Traffic Light status)				Apr-24		
Green	Alginate antacid				Jun-24		

Green	Alverine with Simeticone			Irritable bowel syndrome	Jun-24		
Green	Aminophylline hydrate tablets			Indicated in adults and children aged 6 years and above for the treatment and prophylaxis of bronchospasm associated with asthma, chronic obstructive pulmonary disease and chronic bronchitis. Indicated in adults for the treatment of left ventricular and congestive cardiac failure	Aug-24		
Green	Amlodipine			Hypertension Chronic stable angina pectoris Vasospastic (Prinzmetal's) angina.	Jul-26		
Green	Aspirin			All licensed indications & off-licensed use for hypertension in pregnancy	Nov-25		Aspirin in pregnancy NICE information
Green	Beclometasone /formoterol/glycopyrronium inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Beclometasone inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Beclometasone/ Formoterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Betamethasone plasters			Corticosteroids (topical)	Aug-24		Betamethasone Plasters BNF information
Green	Bilastine			Antihistamine	Mar-26		Follow Place formularies / guidelines for further information
Green	Bimatoprost + timolol				Mar-25		

Green	Bismuth subcitrate potassium , metronidazole , tetracycline hydrochloride 14mg/125mg/125mg	Pylera ®		Helicobacter Pylori eradication	May-26		Green for first line or second line use only to treat H.Pylori in those with penicillin allergy. See link for clinical scenarios where consideration may be indicated. Note the licensed treatment is for 10 days.
Green	Brimonidine gel			Facial erythema of rosacea	Jun-24		
Green	Budesonide inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Budesonide/formoterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Buprenorphine			Pain	Feb-26		
Green	Bupropion			Please refer to Place Commissioned services and guidance documents in exceptional circumstances. Patients who are unable to access these services. Primary care can prescribe. Please seek cks for supporting information	Oct-24		
Green	Canagliflozin			Type 2 diabetes in adults	Nov-24		
Green	Cetirizine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		Follow Place formularies / guidelines for further information
Green	Chlorphenamine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		Follow Place formularies / guidelines for further information
Green	Cimetidine				Jun-24		
Green	Ciprofloxacin			Only as per NICE CKS antibiotics	Jun-24		

Green	Clindamycin/Tretinoin gel			Topical preparations for acne	Jun-24		
Green	Co-codamol 8/500mg for acute pain in adults			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		
Green	Covid-19 vaccine			Covid -19 vaccine-as per NHS green book	May-23		
Green	Cyanocobalamin 50 microgram tablets (dual traffic light classification)	Cyanocominn®		As per NHSE guidance - only to be prescribed in those with medically diagnosed deficiency, including for those patients who may have a lifelong or chronic condition or have undergone surgery that results in malabsorption. Continuing need should however be reviewed on a regular basis. OTC advised if deficiency dietary related	May-23		
Green	Cytisinicline (cytisine)			To aid smoking cessation	May-26		Commissioned services must be used as the standard pathway. Primary care prescribing is only permitted in exceptional circumstances where these services are inaccessible. Please see CKS for supporting information (Cytisinicline Prescribing information Smoking cessation CKS NICE)
Green	Dapagliflozin			Chronic heart failure with preserved or mildly reduced ejection fraction & Chronic kidney disease & Type 2 diabetes	Mar-26		SY Prescribing Guidelines For The Use Of SGLT2 Inhibitors In The Management Of Chronic Heart Failure
Green	Daridorexant			Insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months, in line with the SYICB insomnia management pathway and NICE TA.	Mar-26		SY Daridorexant information
Green	Dekas plus liquid (dual traffic light classification)			Children under 3 years with Cystic fibrosis Also see Grey Traffic Light Status	Oct-23		

Green	Desloratadine			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		
Green	Desogestrel 75microgram, Drospirenone 4mg, Levonorgestrel 30micrograms, Norethisterone 250micrograms	Prescribe as generic		Progestogen-Only Contraceptives	Jun-26		SY Oral Contraception prescribing formulary
Green	Dexamethasone sodium phosphate eye drops				Jun-24		
Green	Diclofenac 3% gel	Solaraze®		Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance
Green	Diltiazem 2% cream/ ointment			anal fissure	Jun-24		
Green	Dorzolamide eye drops				Jun-24		
Green	Dorzolamide/timolol eye drops				Jun-24		
Green	Doxylamine & Pyridoxine	Xonvea®		Nausea and vomiting during pregnancy	Apr-24		
Green	Drospirenone	Slynd®		Refer to Place based formularies	Dec-23		
Green	Dutasteride				Jun-24		
Green	Dydrogesterone			For women with progesterone insufficiencies	Oct-25		
Green	Empagliflozin			Chronic heart failure & Chronic kidney disease & Type 2 diabetes	Mar-26		SY Prescribing Guidelines For The Use Of SGLT2 Inhibitors In The Management Of Chronic Heart Failure
Green	Enalapril				Jun-24		
Green	Ertugliflozin			Type 2 diabetes	Nov-24		

Green	Escitalopram			Treatment of major depressive episodes, panic disorder with or without agoraphobia, social anxiety disorder (social phobia), generalised anxiety disorder and obsessive-compulsive disorder in adults	Aug-25		
Green	Esomeprazole				Jun-24		
Green	Estetrol + drospirenone				Jun-24		
Green	Estradiol and Progesterone				Jun-24		
Green	Estradiol plus Nomegestrol				Jun-24		
Green	Estradiol transdermal spray				Jun-24		
Green	Estradiol Valerate, dienogest	Qlaira		oral contraception	Aug-24		FSRH Clinical Guideline: Contraception for Women Aged over 40 Years
Green	Estriol pessary				Jun-24		
Green	Estriol 1 mg/g vaginal cream				Oct-24		
Green	Estriol gel				Jun-24		
Green	Ethinylestradiol / Desogestrel			Combined Oral Contraceptives Refer to the SY oral contraception formulary for first line and second line product choices	Jun-26		SY Oral Contraception prescribing formulary
Green	Ethinylestradiol / Drospirenone			Combined Oral Contraceptives Refer to the SY oral contraception formulary for first line and second line product choices	Jun-26		SY Oral Contraception prescribing formulary
Green	Ethinylestradiol / Gestodene			Combined Oral Contraceptives Refer to the SY oral contraception formulary for first line and second line product choices	Jun-26		SY Oral Contraception prescribing formulary

Green	Ethinylestradiol / Levonorgestrel			Combined Oral Contraceptives Refer to the SY oral contraception formulary for first line and second line product choices	Jun-26		SY Oral Contraception prescribing formulary
Green	Ethinylestradiol /Norgestimate			Combined Oral Contraceptives Refer to the SY oral contraception formulary for first line and second line product choices	Jun-26		SY Oral Contraception prescribing formulary
Green	Fesoterodine fumarate				Jun-24		
Green	Fexofenadine			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		
Green	Fludrocortide			Refer to Place based formularies/guidelines for alternative listing	Jun-24		Medicines Optimisation Information
Green	Fluorouracil cream			Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance
Green	Fluoxetine (with the exception of the 10mg tablet formulation - refer to the grey entry)			SSRI	Mar-26		
Green	Fluticasone /Salmeterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Fluticasone furoate /umeclidinium /vilanterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Fluticasone furoate/vilanterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Fluvastatin 20mg & 40mg				Jun-24		

Green	Folic Acid				Jun-24		
Green	Formoterol /glycopyrronium /budesonide inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Gestodene/ethinylestradiol				Jun-24		
Green	Glyceryl Trinitrate ointment			anal fissure	Jun-24		
Green	Glycopyrronium /formoterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Hepatitis A vaccine			Immunisation-as per NHS green book	Sep-23		
Green	Hepatitis B vaccine			Immunisation-as per NHS green book	Sep-23		
Green	Hydrocortisone (topical)				Jun-24		
Green	Hydrocortisone eye drops				Jun-24		
Green	Hydroxocobalamin (dual traffic light)			Pernicious anaemia and other macrocytic anaemias (prophylaxis & treatment)	Sep-25		
Green	Hydroxyzine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		Follow Place formularies / guidelines for further information
Green	Ibandronic acid 150mg			Osteoporosis	Jun-24		
Green	Ibuprofen			Cross reference to Traffic Light Status Grey in line with self care guidance	Jun-24		
Green	Imiquimod cream			Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance

Green	Indacaterol / glycopyrronium inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Influenza vaccine			Active immunisation for the prevention of influenza disease	Nov-25		
Green	Insulin needles<£5 per 100 needles			Refer to Place based formulary/ guidelines/other resources for further details	Sep-23		Medicines Optimisation Information
Green	Intravaginal device and pessaries			Non-surgical management of pelvic floor dysfunction	Feb-26		Prescribe on specialist recommendation and in line with NICE guidance
Green	Ipratropium Bromide			Refer to Place based Asthma/ COPD guidelines	Jun-24		Asthma and COPD Information
Green	Isosorbide mononitrate				Jun-24		
Green	Ivermectin 3mg tablets (dual traffic light status)			Treatment of scabies Traffic Lighted as Red for all other indications	Nov-24		
Green	Latanoprost + timolol eye drops			Refer to Place Glaucoma guidelines	Oct-24		Place Glucoma Guidelines
Green	Levocetirizine				Jun-24		
Green	Levofloxacin tablets			Antibiotic	Aug-24		Levofloxacin NICE information
Green	Levomepromazine			The 6.25mg tablet is more cost effective than the 6mg tablet.	Mar-24		
Green	Levonorgestrel				Jun-24		
Green	Levonorgestrel intrauterine delivery system				Jun-24		

Green	Linezolid Traffic lighted Green only in Rotherham (Traffic Lighted Red for all other Places)			Arrangements for the access to antimicrobials for Rotherham Community-based Patients with Infections in whom Linezolid are the only treatment options on advice from microbiology	Jul-26		Rotherham Place Information
Green	Lodoxamide eye drops				Jun-24		
Green	Loratadine			Antihistamine Cross reference to Traffic Light Status Grey in line with self care guidance	Mar-26		Follow Place formularies / guidelines for further information
Green	Macrogol 3350 sachet				Jun-24		
Green	Mebeverine				Jun-24		
Green	Melatonin (2mg m/r) (Dual traffic light classification)			Insomnia in adults aged 55 years and over	Jun-26		Inline with the SY insomnia adult pathway
Green	Meloxicam			NSAID	Oct-25		Refer to Place based formularies
Green	Methenamine hippurate 1g tablets			Urinary tract infection	Apr-23		NICE NG112
Green	Mirabegron			In line with positive NICE TA recommendations			Mirabegron NICE Information
Green	Misoprostol (multiple traffic light classifications)			GI and musculoskeletal	Oct-25		
Green	Mometasone including combination products			Refer to Place based Asthma/ COPD guidelines	Jun-24		Asthma and COPD Information
Green	Morphine sulphate			Cross reference Traffic Light Status Red	Jun-24		
Green	Nabumetone				Jun-24		

Green	Nicotine replacement products eg Patches,gum,lozenges,inhalators, sprays and sublingual tablets			Please refer to Place Commissioned services and guidance documents in exceptional circumstances. Patients who are unable to access these services. Primary care can prescribe. Please seek CKS for supporting information	Oct-24		
Green	Nifedipine				Jun-24		
Green	Ofloxacin			Only as per NICE CKS antibiotics	Jun-24		
Green	Olopatadine hydrochloride, Mometasone furoate monohydrate	Ryaltris		Indicated in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis	May-24		
Green	Ondansetron				Jan-26		
Green	Oral Combined hormone contraception				Aug-24		
Green	Ospemifene tablets			Treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms	May-26		When prescribed in line with NICE NG23 1.5.11
Green	Phenazone 40mg/1g, Lidocaine 10mg/1g ear drops	Otigo®		Local symptomatic treatment and relief of pain in the middle ear	Apr-23		NICE NG91
Green	Pneumococcal polysaccharide conjugate vaccine			Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals aged 18 years and older	Apr-26		Pneumococcal: the Green Book, Chapter 25
Green	Potassium Chloride Syrup 7.5% (equivalent to 1 mmol K+ per ml)			For the treatment of hypokalaemia and potassium deficiency of renal and extrarenal origin.	Jul-26		
Green	Prasterone pessaries			Treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms	May-26		When prescribed in line with NICE NG23 1.5.10

Green	Pregabalin			Neuropathic pain	Apr-25		
Green	Primidone			Essential tremor	Feb-26		
Green	Promethazine			Antihistamine	Mar-26		Follow Place formularies / guidelines for further information
Green	Rehydration solutions/sachets (dual traffic light status)			For all other conditions than acute diarrhoea	Feb-24		
Green	Respiratory syncytial virus vaccine				Dec-23		RSV Green Book Chapter updated February 2025
Green	Rimegepant (Dual classification)			Treatment of acute migraine (cross reference to Amber G classification)	Jul-24		Neurology:migraine management guidelines
Green	Salbutamol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Salmeterol including combination products			SY Asthma/ COPD guidelines	Jun-24		Asthma & COPD guidelines and Information
Green	Sildenafil (generic) (For Erectile Dysfunction) 25mg,50mg,100mg (multiple traffic light classifications)			Erectile Dysfunction. See also entries in grey and red sections. Follow Place formularies / guidelines for further information	Apr-25		Erectile Dysfunction Information
Green	Sildenafil citrate			Erectile dysfunction	Sep-25		
Green	Spironolactone				Feb-25		
Green	Tadalafil 5mg (daily)			Refer to place based formularies for further details	Jul-25		Medicines Optimisation Information

Green	Tadalafil 10mg & 20mg (generic) (For Erectile Dysfunction) (multiple traffic light classifications)			Erectile Dysfunction. See also entries in grey and red sections. Follow Place formularies / guidelines for further information	Apr-25		Erectile Dysfunction Information
Green	Tiotropium /olodaterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Tirbaniulin ointment	Klisyri®		Treatment for Actinic Keratosis	Nov-25		SY Actinic Keratosis Guidance
Green	Tirzepatide (cohort One & Two weight management patients only) [Multiple traffic light classifications]			Traffic Lighted as Green for cohort One & Two weight management patients only (refer to local clinical guidance for further information).	Nov-25		Tirzepatide weight management Information
Green	Tozinameran + famtozinameran	Comirnaty® Original/Omicron BA.4/5		Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals aged ≥12 years who have previously received at least a primary vaccination course against COVID-19	Jun-23		
Green	Umeclidinium/vilanterol inhaler			Used in the treatment of Asthma & COPD	Jun-26		Please refer to SY Asthma and COPD guidance documents. Consider using the lowest cost product which meets the needs of the individual patient.
Green	Vardenafil			Erectile Dysfunction. Follow Place formularies / guidelines for further information	Nov-25		Erectile Dysfunction Information
Green	Varenicline			Please refer to Place Commissioned services and guidance documents in exceptional circumstances. Patients who are unable to access these services. Primary care can prescribe. Please seek CKS for supporting information	Oct-24		Medicines Optimisation Information

Green	Vibegron			Treating symptoms of overactive bladder syndrome	Oct-24		NICE TA999
Green	Zolpidem			Short-term treatment of insomnia in adults in situations where the insomnia is debilitating or is causing severe distress for the patient	Sep-25		